WO1994019355A1 - Chemical compounds useful in photodynamic therapy and production of laser light - Google Patents

Chemical compounds useful in photodynamic therapy and production of laser light Download PDF

Info

Publication number
WO1994019355A1
WO1994019355A1 PCT/US1994/002033 US9402033W WO9419355A1 WO 1994019355 A1 WO1994019355 A1 WO 1994019355A1 US 9402033 W US9402033 W US 9402033W WO 9419355 A1 WO9419355 A1 WO 9419355A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
group
laser
lower alkyl
Prior art date
Application number
PCT/US1994/002033
Other languages
French (fr)
Inventor
Lee Roy Morgan
Joseph H. Boyer
Original Assignee
Bo-Dekk Ventures, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bo-Dekk Ventures, Ltd. filed Critical Bo-Dekk Ventures, Ltd.
Priority to EP94909795A priority Critical patent/EP0684950A4/en
Priority to JP6519283A priority patent/JPH08509471A/en
Publication of WO1994019355A1 publication Critical patent/WO1994019355A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B57/00—Other synthetic dyes of known constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials

Definitions

  • the present invention generally relates to chemical compounds and compositions that are useful as laser dyes and in photodynamic therapy.
  • dye lasers are used for a variety of purposes in numerous technical fields including medicine and applied physics. For example, they may be used to conduct spectral analysis of chemical compounds. Also, they are useful in facilitating the analysis of photosynthetic and biomolecular reaction processes. Dye lasers in the medical field are used for numerous applications including cancer therapy, ophthalmological studies, surgeries and the like.
  • the lasing materials used in dye laser systems consist of fluorescent organic dye compounds dissolved in a liquid solvent.
  • fluorescent organic dye compounds dissolved in a liquid solvent.
  • one of the most important capabilities of dye lasers is their high degree of wavelength tunability.
  • the wavelength output of conventional dye lasers may be scanned over a 10-40 nm range.
  • laser light output can be achieved at wavelengths from near ultraviolet to near infrared.
  • Dye lasers are capable of being tuned because the chemical dyes which they use have specific vibrational and rotational energy levels which can be characterized.
  • dyes for use in dye lasers are presently accomplished by trial and error. Numerous organic compounds showing strong fluorescence have been synthesized and are commercially available. However, very few of these materials are suitable for use in dye lasers. Most commercially used laser dyes primarily consist of coumarin and rhodamine compositions. These dyes, along with other commercially available materials, have only moderate energies and relatively high degrees of photodecomposition. In addition, many dyes require excitation using fiashlamp systems with steep risetimes of 1 microsecond or less. Flashlamps meeting these requirements are difficult to construct for operation above 200 Joules.
  • PDT photodynamic therapy
  • the first mechanism typically involves hydrogen atom abstraction from the drugs, thereby producing free radicals. Subsequent reactions of the radical products with other organic molecules or with oxygen results in biochemical destruction of the diseased tissue.
  • the other reaction mechanism (Type II) normally involves energy transfer from the electronically excited drugs to oxygen, producing singlet molecular oxygen which consequently reacts with a variety of substrates to produce oxygenated products. This pathway can also result in electron transfer from the excited drug to oxygen, producing an oxidized drug product in combination with superoxide ions.
  • This reaction mechanism along with the first mechanism described above, is schematically presented in the following formula:
  • Photofrin II a purified version of hematoporphyrin
  • Other photosensitizing drugs used in photodynamic therapy procedures include phyhalocyanines (merocyanine 540), substituted prupurines, xanthenes (Rhodamine 123 6G&B) cationic cyanine dyes, chlorine polymers, chalcogenapyrylium dyes containing selenium or tellurium atoms in the
  • Fluorescence as used herein is defined as a spontaneous random emission of light resulting from the transition of a molecule from the excited singlet state (S 1 ) to the ground state (S 0 ). Many photochemical reactions arise from the triplet state (T 1 ). However, most photochemical drugs accumulate in a triplet state due to intersystem crossing. These triplet molecules consequently absorb light more or less efficiently, depending on the magnitude of their triplet state absorption and concentration.
  • An even further object of the invention is to provide an improved photodynamic therapy method using photosensitizing chemicals having reduced T-T absorption with a minimum overlap of fluorescence emission and that are cytotoxic.
  • the present invention involves improved laser dye compositions which are superior to previously used dyes in a variety of ways.
  • the dyes described herein have reduced T-T absorption and a lower laser action threshold. This enables the use of flashlamps with slower risetimes. These flashlamps have a longer functional life because they operate at lower driving voltages. Furthermore, a more efficient conversion of the flashlamp pump light due to reduced T-T absorption enables the production of a higher intensity laser beam.
  • the dyes described herein have improved photochemical stabilities which result in reduced degradation of the dye materials.
  • the materials described herein involve a substituted tricyclic compound having the following structures:
  • R 1 is selected from the group consisting of C, N, B, preferably C and N, most preferably C;
  • R 2 , R 3 , R 5 , R 6 , R 8 , R 9 , R 1 1 , and R 12 are independently selected from the group consisting of C and N, wherein R 6 and R 8 are preferably N, and R 2 , R 3 , R 5 , R 9 , R 1 1 and R 12 are preferably C;
  • R 4 and R 10 are independently selected from the group consisting of C, N, O, and S, preferably C;
  • R 7 is selected from the group consisting of C, N, B, preferably B;
  • R 20 and R 21 are independently selected from the group consisting of H, F, phenyl, naphthyl, and C n H 2n+ 1 where n is an integer from 1 to 4, and R 20 and R 21 are preferably F; and
  • R 13 , R 14 , R 14 , R 17 and R 18 are all preferably lower t-alkyl or n-alkyl, most preferably methyl or ethyl, and R 16 and R 19 may also be lower t-alkyl or n-alkyl, and R 1 -R 21 can be any subgroup of the listed substituents.
  • R 22 -R25 are lower t-alkyl or n-alkyl, preferably ethyl and/or t-butyl/n-butyl.
  • R lower t-alkyl or n-alkyl or CN
  • W lower t-alkyl or n-alkyl or CN
  • Particularly preferred compounds include (b), (c) or (d), or any combination thereof.
  • X is lower alkyl or sulfonate (or pharmaceutically acceptable sulfate salts), or more preferably lower t-alkyl or n-alkyl
  • Y is lower alkyl, more preferably lower t-alkyl or n- alkyl, for example methyl, ethyl, propyl or butyl.
  • cytotoxic injury is induced in targeted tissue by introducing the compound into or adjacent the targeted tissue.
  • the targeted tissue is exposed to a sufficient amount of light of a sufficient wavelength for a sufficient period of time to cause injury to the targeted tissue.
  • the compound may be administered to the subject by systemic (for example, intravenous) administration, local injection into the target tissue, or topical application to the target tissue.
  • the targeted tissue may be exposed to a light source such as a laser, a sun lamp, or a fiber optic illumination system, such as an endoscope.
  • FIG. 1 is a graph of laser energy output as a function of energy for several compounds of the invention (4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s -indacene and the disodium salt of 4,4-difluoro-1,3,5,7,&entamethyl-4-bora-3a,4a-diaza- s-indacene-2,6 disulfonic acid monohydrate) in comparison with previously known laser dyes (Rhodamine 6G and Coumarin 545).
  • FIG. 2 is a graph representing the absorption and fluorescence spectra of a compound of the invention (4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene) dissolved in ethanol.
  • FIG. 3 is a bar graph showing the percentage inhibition of growth of human ovarian tumor cells in vitro following treatment of the cells with a compound of the present invention and exposure to light.
  • improved chemical compounds and compositions which have a variety of uses. They are especially useful as dye media in laser systems, and as photochemical agents in photodynamic therapy techniques.
  • dye laser systems many of the compounds have a power output, photostability and solubility that is superior to currently available dyes, including coumarin and rhodamine-based compositions.
  • photodynamic therapy techniques they are highly effective in destroying targeted tissues.
  • the tricyclic structure shown above has the following substitution pattern:
  • R 1 -R 5 C
  • R 13 -R 15 CH 3
  • R 7 B
  • R 17 -R 18 CH 3
  • R 20 -R 21 F
  • FIG. 2 shows the absorption (S-S) and fluorescence (FL) spectra of the compound of Example I (designated PMP-BF 2 ) dissolved in ethanol.
  • the T-T absorption spectrum was recorded at 77K, employing a 1 x 10 -4 molar solution of 2-methyltetrahydrofuran as solvent.
  • a suspended yellow solid was isolated by filtration, dissolved in 75 ml water and the solution was neutralized with sodium bicarbonate (0.30 grams). Sodium bicarbonate was continuously added thereafter until effervescence stopped. The aqueous solution was concentrated to approximately one-quarter its previous volume. Upon the addition of about 15 ml of ethanol, a yellow precipitate appeared which was isolated and dried in a desiccator under vacuum.
  • the precipitate weighed approximately 0.66 grams, had a melting point of about 260°C, and represented the final product (the sodium salt of 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s- indacene-2,6-disulfonic acid monohydrate-[C 14 H 15 BF 2 N 2 O 6 S 2 Na 2 .H 2 O]). Production of this product is shown in the following basic reaction:
  • the product With respect to its use as a laser dye, the product had a lasing threshold of 10 kV with a lasing wavelength range of 545-585nm. This data was obtained using a 60 mg quantity of product dissolved in 230 ml of H 2 O in a 10 mm flashlamp dye laser manufactured by the Phas-R Company (Model D-1100).
  • Example II As in Example I, tests were conducted on the product in Example II in order to determine its fluorescence in various solvents. Data showing a variety of different solvents combined with the product of Example II is presented below in Table II:
  • the tricyclic structure of this Example has the following substitution pattern:
  • R 3 C
  • R 14 CH 2 CH 3
  • FIG. 1 shows the laser output E (in mJoule) as a function of input energy E (in Joule) of a 1.5 x 10 -4 molar solution of the compound of Example I (designated PMP-BF 2 ) dissolved in ethanol, a 2 x 10 -4 molar solution of Coumarin 545 dissolved in ethanol, a 2 x 10 -4 molar solution of Rhodamine 6G dissolved in ethanol, and a 2 x 10 -4 molar solution of the compound of Example II (designated PMP-BF 2 -sulfonate) dissolved in ethanol.
  • EXAMPLE IV EXAMPLE IV
  • Candela LFDL-8 laser with flashlamp excitation at a pulsewidth of 2 ⁇ sec, and a risetime 0.7 ⁇ sec.
  • P-BF 2 dyes homogeneously dispersed in an acrylic co-polymer were found to be superior "solid-state" lasers with the special feature of tunability characteristic of a laser dye.
  • PMDEP-BF 2 (10 -4 M) in a polymer matrix (5 parts methyl methacrylate and 1 part hydroxypropyl acrylate) gave a power efficiency of 88%.
  • R- 6G under similar treatment gave an unsatisfactory performance and was not measured; sulforhodamine-B gave a 37% efficiency.
  • the PMDEP-BF 2 and PMPDS were found to be particularly soluble in the polymer matrix.
  • the polymer matrix is disclosed in U.S. Patent No. 5,136,005which is incorporated by reference. Any laser dye of the present invention may be substituted for the dye in any of the examples of that incorporated patent.
  • the matrix generally includes solid polymeric host laser rods prepared using bulk polymerization of acrylic acid ester comonomers. When the polymer is admixed with dyes capable of supporting laser oscillation and poiymerized with a free radical initiator under mild thermal conditions, a solid product is produced having efficient lasmg properties.
  • dyes of the present mvention have been found to have superior solubility in these polymer matrices, which in turn increases the efficiency of lasing action.
  • the group of fused lmear 6,6,6-tricyclic ring systems contains the dye rhodamine 6G (R - 6G) 1.
  • This laser dye had the highest power efficiency from flash lamp pumping known at the time of its discovery.
  • the cyanine dyes 2 were recognized for the ability of their luminophors in providing laser activity in the longer wavelengths, particularly > 800 nm.
  • R is a substituent such as alkyl
  • X is an anion
  • m 0 or 1
  • n 0-5.
  • Structures 3a, ⁇ las 541 nm, and 3b, ⁇ las 800 nm, are typical cyanine dyes.
  • the invention includes any combination of the compounds in Table II, or any combination thereof
  • Compounds 7h and 7i each have a four carbon bridge -(CH 2 ) 4 - as substituents Y and Z.
  • Compound 7j has a three carbon bridge -(CH 2 ) 3 - as substituents X and Y, that forms a five membered ring (see Example VII).
  • the parent linear 5,6,5-tricyclicantiaromatic (4n ⁇ e) hydrocarbon, s-indacene C 12 H 8 was a red solid but was not described as fluorescent.
  • the parent 6,6,6-tricyclicaromatic (4n + 2 ⁇ e) hydrocarbon, anthracene C 14 H 10 showed ⁇ f 400 nm.
  • Ethyl 3,5-dimethyl-4-tertbutylpyrrole-2-carboxylate 4g was prepared from ethyl 3,5-dimethylpyrrole-2-carboxylate 4a in an alkylation with tert-butyl acetate.
  • phosphoric acid provided a convenient preparation of pyrrole 5b and was extended to
  • 2,4-dimethyl-3-tert-butylpyrrole 5g led instead to the replacement of both the carboethoxy and tert-butyl groups with hydrogen to give 2,4-dimethylpyrrole 5a.
  • the pyrroles 5g, j, k were obtained from ethyl 3,5-dimethyl-4-tert-butylpyrrole-2-carboxylate 4g, ethyl
  • Kryptopyrrole 5c condensed with propionyl chloride, isobutyryl chloride, cyclohexanecarbonyl chloride, acetoxyacetyl chloride, and p - dimethylaminobenzoyl chloride to produce the 8-ethyl, 8-isopropyl, 8-cyclohexyl, 8-acetoxy methyl, and 8-dimethylaminophenyl derivatives 7o-s of 1,3,5,7-tetramethyl-2,6-diethylpyrromethene - BF 2 complex.
  • 1,7-diphenyl-3,5-dimethylpyrromethene - BF 2 complex 7w An assumed unisolated pyrromethene hydrobromide intermediate 6x from the pyrrolecarboxylate ester 4g was converted to 1,3,5,7-tetramethyl-2,6-di- tert-butylpyrromethene - BF 2 complex 7x.
  • each of these seven dyes showed high extinction coefficients log e 4.8 to 4.9 and high fluorescence quantum yields ⁇ f 0.67 to 0.99.
  • PMP - BF 2 7a, PMDEP - BF 2 7c, and the 2,6-di-n-butyl derivative 7e were superior to the other four 2,6 - dialkyl derivatives in laser activity RE (relative efficiency in power output where RE 100 is arbitrarily assigned to rhodamine -6G).
  • the bistetramethylene dyes 7h, i and the bistrimethylene dye 7j gave nearly identical ⁇ max with high extinction coefficients log ⁇ > 4.8 and shared strong fluorescence ⁇ f ⁇ 0.8 they differed significantly in laser activity with RE ⁇ 75 for the bistetramethylene dyes and RE 20 for the bistrimethylene dye, Table VI.
  • the structure for the dye 7j was confirmed by an X-ray crystallographic analysis to have chromophore planarity with negligible strain. Hence compounds 7 are preferred wherein Y is n-alkyl or t-alkyl containing an even number of carbons, especially 2 or 4 carbons.
  • 1,3,5,7-tetramethyl-2,6-diethyl-8-cyanopyrromethene - BF 2 complex 7bb presented exceptional interest.
  • Four cyano substituted laser dyes were listed by Maeda in Laser Dyes, Academic Press, Tokyo, Japan, 1984, pp. 19-21.
  • 1,3,5,7-tetramethyl-8-ethylpyrromethene-2,6-disulfonic acid - BF 2 complex 17 showed RE 50.
  • Low values were also obtained for the disulfonate ester 18 RE 35, the dicarboxylate ester 19 RE 50, the 2,6-diacetamido derivative 7m RE 5 and the 2,6-diphenyl derivative 71 RE 20.
  • the singular example of 1,7-dimethoxy-2,3,5,6,8-pentamethylpyrromethene - BF 2 complex 7n RE 30 suggested that laser activity was diminished by electron donating substituents at the
  • FTIR FTIR, Varian Gemini 300 NMR, Hewlett-Packard 5985 (70 eV) GC-MS, Cary 17 (UV), and Perkin-Elmer LS-5B Luminescence spectrometer.
  • a dye laser was constructed and operated in the non-flowing (static) mode and had no tuning capability.
  • the dye cell (2.5 mm diameter, 50 mm long) had an elliptical cavity configuration of small eccentricity.
  • the flashlamp EG & G model FX 139C-2 produced a pulse that had a rise time of 200 ns, half-width length of 600 ns, and input energy of 2 J at 6.32 kV, 5 J at 10.00 kV, 7.2 J at 12.00 kV, and 10 J at 14.14kV.
  • pyrroles included ethyl 3,5-dimethylpyrrole-2-car- boxylate 4a, ethyl 3,4-diethyl -5-methylpyrrole-2-carboxylate 4k, 2,4-dimethyl 3-ethylpyrrole 5c (kryptopyrrole), and 4,5,6,7-tetrahydroindole 5h.
  • pyrroles and pyrromethene derivatives were prepared by the methods cited: ethyl 3,5-dimethyl-4-ethyl ⁇ yrrole-2-carboxylate 4c (Kleinspehn, J. Amer. Chem. Soc. 77: 1546,1955), ethyl 3,4-diethyl-5-methylpyrrole-2-carboxylate 4k (Wang and Chang, Synthesis, p. 548, 1979), ethyl 3-phenyl-4-ethyl-5 methylpyrrole-2-carboxylate 4o (Ogoshi et al., Tetrahedron Lett. 24:929, 1983); Guy and Jones, Aust. J. Chem.
  • Ethyl 3,5-dimethyl-4-n-propylpyrrole-2-carboxylate4d A solution of sodium nitrite (28.2 g, 0.41 mol) in water (100 ml) was added to a stirred cold solution of ethyl acetoacetate (49.4 g, 0.38 mol) in acetic acid as the temperature was held below 15 °C. After the solution was stirred and stored overnight at 25 °C, 3-n-propyl-2,4-pentanedione (53.7 g, 0.38 mol) and zinc (53 g) were sequentially added and the mixture was stored at 60°C for 1 h.
  • Ethyl 3,5-dimethyl-4 -tert-butylpyrrole-2-carboxylate4g A solution of acetic acid (5.0 ml), sulfuric acid (1.2 ml), ethyl 3,5-dimethylpyrrole-2-carboxylate 5a (5.0 g, 0.03 mol) and tert-butyl acetate (3.5 g, 0.03 mol) was heated at 75 °C for 2 h and combined with sodium carbonate (8 g) in ice water (100 ml) to bring about the precipitation of ethyl
  • Ethyl 3-methyl -2,4,5,6-tetrahydrocyclopenta-[c]pyrrolecarboxylate 4j A procedure for the synthesis of pyrroles via N-(3-oxo-1-alkenyl)glycine ester was adapted from Hombrecher and Horter, Synthesis 389, 1990. Ethyl aminoacetate hydrochloride (28 g, 0.20 mol) and triethylamine (20.1 g, 0.20 mol) were added to a solution of 2-acetylcyclopentanone (25.0 g, 0.20 mol) in ethanol (400 ml). The solution was stirred at room temperature for 15 hours and concentrated.
  • Trifluoroacetyl - 3 ,5 - dirnethylpyrrole 12 Trifluoroacetic anhydride (15.8 g, 75 mmol) was added dropwise with stirring to a solution of 2,4-dimethylpyrrole 5a (9.6 g, 50 mmol) in benzene (140 ml) at 0 °C. The mixture was stored at 0°C for 3 h and washed with water (25 ml). The separated organic layer was dried (magnesium sulfate), concentrated, and chromatographed (silica gel, hexanelethyl acetate, 3/1) to give
  • 3-methyl-2,4,5,6-tetrahydro-cyclopenta[c]pyrrolecarboxylate 4j (9.1 g, 0.04 mol) and potassium hydroxide (26 g, 0.47 mol) in ethanol (200 ml) was heated at 80°C for 4 hours and concentrated. The residue was combined with ice water (400 ml), and made slightly acidic by the addition of acetic acid to bring about the precipitation of crude 3 - methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrrolecarboxylicacid. The crude acid was combined with ethanolamine (5 g), heated at 180°C for 1 hour, and diluted with ice water (100 ml).
  • Each salt 6u, v, x, y and 14 was converted by treatment with boron trifluoride etherate as described above to the corresponding P - BF 2 dye 7u, v, x, y, and 7w (see Table II). Treatment of the pyrromethene hydrobromide 14 by boron trifluoride etherate also brought about deacylation.
  • Diethyl 1,3,5,7-tetramethyl-8-cyanopyrromethene-2,6-dicarboxylate-BF 2 complex 7aa and 1,3,5,7-tetramethyl-2,6-diethyl-8-cyanopyrromethene-BF 2 complex 7bb offered examples of P- BF 2 dyes with electron withdrawing substituents at the 8-position.
  • New heterocycle-BF 2 dyes are needed to extend the spectral range of the P- BF 2 dyes disclosed above. These above disclosed dyes have a spectral range of 520-620 nm, but it would be advantageous to broaden this range to 300-800 nm.
  • Photodynamic therapy for cancer is preferably performed with dyes which have luminescence near 620 nm for maximum tissue penetration. In these and other examples success depends on laser beam tunability, a feature characteristic of organic laser dyes but not generally encountered in solid state lasers. Structures for such dyes are given below, along with synthesis procedures and methods of proposed spectroscopic evaluation.
  • I-BF 2 Imidazomethene-BF 2 Complexes
  • 21 is related to but structurally different from the cyanines.
  • the inventors have studied its Lewis acid salt 21-BF 3 , ⁇ f 377 nm ⁇ f 0.93 for laser activity. It has an observed fluorescence at 377 nm, which predicts a red shift to ⁇ f -440 nm ⁇ f ⁇ 0.9 for the more highly conjugated fluorophore in alkylated derivatives 28 of imidazomethene-BF 2 complexes (I-BF 2 ).
  • This blue-green laser beam can be used for underwater communication by flashlamp dye excitation.
  • P-BF 2 with Fluorescence and Laser Activity above 600 nm A red shift in the electronic spectra (absorption, fluorescence, and laser activity) of a dye molecule can be achieved by elongation of the system of conjugated double bonds in the chromophore. This elongation can be achieved by substitution in selected P-BF 2 dyes.
  • Chromophore elongation is also achieved by conversions of 1,5,7,8-tetramethyl-formyl-2,6- diethylpyrromethene-BF 2 complex 36 by the Wittig reaction. March, "Advanced Organic Chemistry,” 4th ed., p. 956, 1992.
  • This versatile method is general for the conversion of aldehydes into functionalized olefins.
  • the aldehyde 36 is treated with a Wittig ylide derived from ⁇ -bromo-propionitrile to produce 1,5,7,8-tetramethyl-3-cyanovinyl-2,6- diethylpyrromethene-BF 2 complex 37.
  • Fluorescence and laser activity of P-BF 2 dyes 35 and 37 and similar derivatives with other conjugated unsaturated substituents at the 2,6-positions are expected near 650 nm and above.
  • X F, CnH2n+1, phenyl
  • an exemplary laser with which the compositions of the invention may be used includes a flashlamp-pumped dye laser system manufactured by the E.G. & G. Corporation (Model No. FX139C-2).
  • This system has a flashlamp capable of producing pulses of approximately 200 ns risetime and 600 ns length at the half-width of the pulse. It is also capable of delivering 2 Joules at 6.32kV, 5 Joules at 10.0 kV, and 10 Joules at 14.14kV.
  • the cell or containment vessel used in the system to retain the dye is about 2.5 mm in diameter and about 50 mm long.
  • the compounds of the invention used as laser dyes may be in a gaseous form, or homogeneously dispersed in a polymer slug (e.g. a plastic such as methyl methacrylate).
  • a polymer slug e.g. a plastic such as methyl methacrylate
  • the compounds Upon excitation, the compounds produce laser light having a high quantum fluorescence yield with low triplet-triplet (T-T) absorption, as well as a high degree of photostability. This improves the overall efficiency of the laser systems with which the dyes are used in comparison with previously used dye materials.
  • T-T triplet-triplet
  • Preferred compounds for use as laser dyes which are encompassed in the scope of this invention include those compounds with a structure:
  • R 1 -R 5 and R 9 -R 12 C.
  • R 1 -R 5 and R 9 -R 12 C and
  • Lasers can be used to produce light that is used to illuminate the targeted tissue area of the present invention.
  • the laser is coupled to one or more fiberoptic cables to propagate light to the tip, with minimal energy loss.
  • the tip may be cleaved for forward light projection; it may be bulb tipped for isotropic spherical distribution; or a cylindrical scattering material can be applied to the fiber tip to distribute light perpendicularly to the fiber axis.
  • the energy delivered will depend on the dosage (the amount of light and the duration of its delivery) of light from the fiber.
  • the light distribution can be calibrated at the tip with a power meter; the dosage of light delivered is preferably gauged to prevent any hyperthermic effects.
  • a most preferred wavelength of the light can be determined from the fluorescence (FL) spectra of the cytotoxic compounds, as in FIG. 2 for PMP-BF 2 .
  • Incident light having a wavelength of about 500-550 nm produced the greatest fluorescence. That would be the most preferred wavelength for light used to illuminate PMP-BF 2 in photodynamic therapy. Similar preferred wavelengths can be readily determined for the other compounds of the present invention.
  • Photodynamic therapy causes early, significant damage to membranes, particularly the plasma membrane, with the formation of multiple membrane blebs. These blebs protrude from the cell membrane and indicate severe membrane damage. This membrane damage is an early observable effect of the cytotoxicity induced by the method of the present invention.
  • cytotoxicity is used in its well-known and commonly accepted medical sense to mean damage to cells.
  • the histologic effects of tumors treated with the photodynamic therapy of the present invention characteristically exhibit an avascular necrosis.
  • a preferred systemic dose of 1.5-2.5mg/kg of subject weight has been found suitable to induce cytotoxic damage in living cells following exposure to a light source, such as a sunlamp, laser, or fiberoptic scope.
  • the photodynamic therapy of the present invention can be used to induce cytotoxic damage to many different types of living tissue.
  • the cytotoxic damage induced by the present method occurs without respect to the tissue type, histologic characteristics, or the presence of receptors.
  • the method is especially useful in treating patients with tumors in numerous anatomic sites, including the skin, bronchus, bladder, esophagus, brain, and gynecological and intra-abdominal tissues.
  • cytotoxic effect of the present invention include basal and squamous cell cancers, malignant melanoma, Kaposi's sarcoma, mycosis fungoides, metatastic epidermoid, and recurrent breast cancer.
  • Head and neck cancers that can be treated with the present method include nasopharyngeal, tongue and other oropharyngeal tumors.
  • target tissues include transitional cell carcinoma of the bladder, endobronchial cancer (such as adenocarcinoma or small cell carcinoma), esophageal cancer (such as adenocarcinoma), gynecologic tumors (such as cervical carcinoma in situ, vaginal cancer and vulvar malignancies) and even brain tumors such as glioblastoma, astrocytoma and metatastic malignancies (such as lung cancer metatastic to the brain).
  • endobronchial cancer such as adenocarcinoma or small cell carcinoma
  • esophageal cancer such as adenocarcinoma
  • gynecologic tumors such as cervical carcinoma in situ, vaginal cancer and vulvar malignancies
  • brain tumors such as glioblastoma, astrocytoma and metatastic malignancies (such as lung cancer metatastic to the brain).
  • Systemic intravenous introduction of the compound is preferably administered in a dosage of 1.5-2.5mg/kg of the subject's body weight, more preferably 2.0 mg/kg.
  • Introduction of the compositions into the body of a subject is accomplished preferably by injection directly into the tumor or by topical application to the affected area.
  • the compound is preferably provided in a 25 mg/ml sterile water solution that can be injected into the tumor or administered intravenously for systemic dosages.
  • a one ml amount of a 25 mg/ml or 0.3 % solution can be thinly coated on an external area of the body to be treated, and then exposed to a light source either immediately or after a few hours.
  • the drug spreads throughout the body and into regions of diseased tissue (e.g., cancer tissue). Thereafter, the diseased target tissue is illuminated using light from a conventional light source (e.g., laser, sun lamp, etc.). In cases of cancer wherein the neoplastic growths are relatively near the skin surface, the light is applied directly through the skin. In other cases where neoplasms are deeper within the body (e.g., in the urinary bladder, gastrointestinal tract, respiratory tract, etc.) the light would be introduced by non-surgical or surgical entry into the body. For example, if the diseased tissue is in the respiratory tract, access could be accomplished by either surgical or non- surgical entry through the mouth using a fiber optic illumination system or the like.
  • a conventional light source e.g., laser, sun lamp, etc.
  • a collimated beam of light (such as a laser) is particularly preferred because a limited area of the body (such as the tumor) can be exposed to the light without illuminating surrounding tissue.
  • the rats were anesthetized using phenobarbital (2mg/kg i.p.) and the injected tumors were exposed to light from either a quartz lamp (100 or 250 w) or an argon laser (with 488/514 and 628 nm frequencies) for 10- 20 minutes.
  • a quartz lamp 100 or 250 w
  • an argon laser with 488/514 and 628 nm frequencies
  • three control groups (1) saline injected, unirradiated tumors; (2) saline injected, irradiated tumors; (3) PMPDS-BF 2 injected, and unirradiated tumors. Tumor necrosis was observed in those tumors injected with PMPDS- BF 2 and 50-100% tumor remission was seen in these cases.
  • Tumors injected with PMPDS- BF 2 that were not irradiated and tumors which were injected with saline solution and received irradiation showed no necrosis or remission.
  • Table VIII The data
  • Al l tumors evaluated had an ini tial total volume of 1 cm 3 or less.
  • ovarian cells from fifteen individual patients were evaluated. All cancers were epithelial originating ovarian adenocarcinomas. Each cancer had been passed through at least one culture in RPMI-1640 (10% FBA) medium prior to use in the present study. In each case cells were harvested and washed in RPMI-1640 medium and resuspended in concentrations of 2.6 x 10 6 cells/ml at 5 °C. The cells (2.6 x 10 6 cells/ml) were then incubated in a RPMI-1640 growth medium (containing 10% fetal bovine albumin, penicillin 100 U/ml and streptomycin 100 ⁇ g.
  • RPMI-1640 growth medium containing 10% fetal bovine albumin, penicillin 100 U/ml and streptomycin 100 ⁇ g.
  • the seeding density for the cells in this study was kept between 1-5 x 10 4 cells per dish and the plates incubated at 37 °C in a CO 2 incubator. Incubation was continued for another 2-3 weeks and the plates examined under an inverted phase contrast microscope and cells counted. Since these cells grow as tight aggregates in soft-agar, it was impossible to determine the number of cells in each growth. Instead, an ocular micrometer was used to count colonies 30 ⁇ m or larger in size. Plating efficiency, defined as the number of colonies formed per 100 viable cells plated, was compared between groups.
  • Ovarian cancer cells three days post exposure to PMPDS-BF 2 (0.04 ⁇ g/ml) plus light were unable to colonize, demonstrated pyknotic changes in the nucleus and cytoplasmic discoloration. The cells retained a yellow-green color for up to four (4) weeks and failed to colonize when resuspended in fresh medium and did not initiate cellular division. With time the cells disintegrated into cellular debris.
  • chemotherapeutic agents and radiation therapy Her cancer continued to progress and she received nine weekly treatments with a topical 0.3% solution of 1, 3, 5, 7, 8-pentamethylpyrromethene boron difluoride-2, 6-disulfonate (PMPDS-BF 2 ) in dimethylsulfoxide applied to the chest wall lesions followed by exposure to a General Electric sunlamp for ten minutes.
  • the patient had initially a greater than 50% shrinkage of her tumor, which lasted over nine weeks. She demonstrated no toxic reactions. After a nine week shrinkage, the metastatic lesions again began to grow.
  • any of the compounds of the present invention are used as in Example X-XII.
  • the term "lower alkyl” refers to an alkyl group having 1-4 carbons.
  • a class of substituents "selected independently” from a group means that any of the substituents can be any of the listed substituents and that the substituents in the class need not be identical (although they may be).
  • electron withdrawing group means a group (such as a CN containing group) that withdraws electron density.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A new group of fluorescent organic compounds having a variety of uses are described. They are especially useful as dye compounds in dye laser systems, and as photochemical agents in the treatment of diseased tissues using photodynamic therapy techniques. The compounds include a tricyclic compound having structure (I). Preferably R1-R5 = R9-R12 = C; R7 = B; R6 and R8 = N; R14 = lower n-alkyl or an electron withdrawing group such as CN-; R16 and R19 are independently selected from the group consisting of lower n-alkyl, a sulfate or an acid or salt thereof, or hydrogen; and R20 = R21 = F. Other compounds include compounds of formula (a), (b), (c), (d), (e).

Description

CHEMICAL COMPOUNDS USEFUL IN PHOTODYNAMIC
THERAPY AND PRODUCTION OF LASER LIGHT
ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT
This invention was made partially with government support under Grant No. ONR (N00014-87-K-0254) awarded by the Department of the Navy, Office of the Chief of Naval Research. The U.S. Government may have certain rights in this invention.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention generally relates to chemical compounds and compositions that are useful as laser dyes and in photodynamic therapy.
2. General Discussion of the Background
A demand currently exists for chemical compounds having a high degree of stability and quantum fluorescence yield. These materials are usable for numerous purposes, including the generation of laser light. Substantial research has been conducted involving chemical laser systems capable of operating in the near UV/visible/near IR spectral regions. Dye lasers offer the greatest promise in meeting these requirements.
In the late 1960s, organic dye lasers tunable over a wide frequency range were developed. The light beams produced by these lasers were capable of being concentrated into an extremely narrow band through the use of diffraction gradient systems or other optical devices. Today, dye lasers are used for a variety of purposes in numerous technical fields including medicine and applied physics. For example, they may be used to conduct spectral analysis of chemical compounds. Also, they are useful in facilitating the analysis of photosynthetic and biomolecular reaction processes. Dye lasers in the medical field are used for numerous applications including cancer therapy, ophthalmological studies, surgeries and the like.
Typically, the lasing materials used in dye laser systems consist of fluorescent organic dye compounds dissolved in a liquid solvent. As discussed in Laurence, C.L.,The Laser Book - A New Technology of Light, Prentice Hall Press, New York, 1986, one of the most important capabilities of dye lasers is their high degree of wavelength tunability. For example, the wavelength output of conventional dye lasers may be scanned over a 10-40 nm range. Through the use of different dye types, laser light output can be achieved at wavelengths from near ultraviolet to near infrared. Dye lasers are capable of being tuned because the chemical dyes which they use have specific vibrational and rotational energy levels which can be characterized.
Laser dye efficiency, laser action threshold, and fiashlamp performance are closely inter-related. Desirable excitation from a large fiashlamp with a slow rise-time requires (1) lower triplet-triplet (T-T) absorption of the laser dye over its fluorescence region ηT( λF), (2) shorter triplet state (phosphorescence) lifetime τp , and (3) laser dye quantum fluorescence yield close to unity ( Θ near 1). (Drexhage in Dye Lasers , Springer Verlag, 1977.) Most of the commercially available and generally used dye molecules accumulate in their triplet state due to intersystem crossing when they are excited by a light source. Many commercially available laser dyes also unfortunately show T-T absorption in the spectral region of their laser action. Other problems with existing laser dyes include poor photostability and thermal stability, and relatively low solubility.
The selection of dyes for use in dye lasers is presently accomplished by trial and error. Numerous organic compounds showing strong fluorescence have been synthesized and are commercially available. However, very few of these materials are suitable for use in dye lasers. Most commercially used laser dyes primarily consist of coumarin and rhodamine compositions. These dyes, along with other commercially available materials, have only moderate energies and relatively high degrees of photodecomposition. In addition, many dyes require excitation using fiashlamp systems with steep risetimes of 1 microsecond or less. Flashlamps meeting these requirements are difficult to construct for operation above 200 Joules.
Chelation of aluminum dichloride by a pyrromethene bidentate ligand has been reported to give an unstable orange solid; light absorption and emission data have not been reported for this compound. Treibs and Kreuzer, Liebigs Ann. Chem. , 718:208,1968; 721:116, 1969. Pyrromethene (P)-metal (M) chelates (P2M) of tetracoordinate zinc, nickel, and copper have shown weak fluorescence above 500 nm ( θ~10-3). Falk et al., Monatsh. Chem. , 718:208, 1968; 721: 116,1969. However, fluorescence is not important for laser activity. Pyrazoboles (dimeric 1-borylpyrazole chelates of dialkylboron (BR2)) and the BF2 complexes of 1,2,3,4- tetrahydro-1,10-phenanthroline have not been found to be fluorescent. Trofimenko, J. Amer. Chem. Soc., 89:3165-3170,1967; 92:5118, 1970; Klebe, et al., Chem. Ber. 116:3125.1983.
Modest laser activity ( λlas420 nm) was reported for a "boratriazinium" salt by
Basting et al., Appl. Phys., 3:81, 1974, however the structure was not established.
Another important use for fluorescent dye compositions involves the detection and treatment of diseased tissues using photodynamic therapy (PDT) techniques. These techniques, traditionally involving the administration of a photosensitizing drug to a patient, result in the distribution of a drug throughout the patient's body. The drugs or chemicals subsequently localize in areas of diseased tissue which is then illuminated with light of an appropriate wavelength to activate the drugs or chemicals. This photoactivation results in photochemical reactions in the diseased tissues that ultimately cause cytotoxic injury and/or death to the tissues.
There are currently two generally proposed mechanisms by which photosensitizing drugs are chemically altered upon illumination by an appropriate light source. The first mechanism (Type I) typically involves hydrogen atom abstraction from the drugs, thereby producing free radicals. Subsequent reactions of the radical products with other organic molecules or with oxygen results in biochemical destruction of the diseased tissue.
The other reaction mechanism (Type II) normally involves energy transfer from the electronically excited drugs to oxygen, producing singlet molecular oxygen which consequently reacts with a variety of substrates to produce oxygenated products. This pathway can also result in electron transfer from the excited drug to oxygen, producing an oxidized drug product in combination with superoxide ions. This reaction mechanism, along with the first mechanism described above, is schematically presented in the following formula:
i
O
Figure imgf000005_0001
Photodynamic therapy has been used experimentally in cancer patients since 1972.
One experimental drug known as Photofrin II (a purified version of hematoporphyrin) has undergone randomized clinical trials in photodynamic therapy. Other photosensitizing drugs used in photodynamic therapy procedures include phyhalocyanines (merocyanine 540), substituted prupurines, xanthenes (Rhodamine 123 6G&B) cationic cyanine dyes, chlorine polymers, chalcogenapyrylium dyes containing selenium or tellurium atoms in the
chromophore, phenothiazinium derivatives, benzophenoxoniums (Nile Blue A) and triarylmethanes (Victoria Blue BO [VB-BO]). The exact mechanisms used by the above chemicals to destroy diseased tissues (including cancer cells) upon exposure to an excitory light source is currently unknown. Moreover, the efficacy of these and other currently used chemicals in photodynamic therapy has not been entirely substantiated, although positive results have been demonstrated in many instances.
Ongoing research has involved a search for photochemicals of improved stability which express minimal side effects. A major side effect caused by currently used drugs is the development of uncontrolled photosensitivity reactions in patients after systemic drug administration. Upon exposure to the sun, patients develop generalized skin
photosensitization. Ongoing research has specifically involved a search for chemicals which avoid these side reactions. As described above, numerous chemicals have been synthesized which show strong fluorescence and potential value as photosensitizing drugs. "Fluorescence" as used herein is defined as a spontaneous random emission of light resulting from the transition of a molecule from the excited singlet state (S1) to the ground state (S0). Many photochemical reactions arise from the triplet state (T1). However, most photochemical drugs accumulate in a triplet state due to intersystem crossing. These triplet molecules consequently absorb light more or less efficiently, depending on the magnitude of their triplet state absorption and concentration.
Thus, a need exists for photosensitizing chemicals which are useful in photodynamic therapy characterized by reduced triplet-triplet (T-T) absorption upon the application of light from an external source. Moreover, a need exists for photosensitizing drugs which are easily activated and are photochemically stable. The present invention satisfies this need, as described below.
It is an object of the present invention to provide improved organic chemicals that are cytotoxic when illuminated.
It is another object of the invention to provide improved organic chemicals that are suitable for use as laser dyes.
It is another object of the invention to provide improved laser dyes that offer a high degree of photochemical stability.
It is another object of the invention to provide improved laser dyes that are readily dissolvable and easy to use.
It is another object of the invention to provide improved laser dyes that offer a high fluorescence quantum efficiency (QF> 0.7).
It is another object of the invention to provide improved laser dyes with low triplet- triplet (T-T) absorption, thereby enabling the use of fiashlamp pumping systems having slower risetimes.
It is another object of the invention to provide improved laser dyes which produce laser light having a higher intensity in comparison with the light beams produced using conventional dyes.
It is another object of the invention to provide an improved method for photodynamic therapy, particularly using chemicals which are stable, readily soluble and easily prepared.
An even further object of the invention is to provide an improved photodynamic therapy method using photosensitizing chemicals having reduced T-T absorption with a minimum overlap of fluorescence emission and that are cytotoxic.
SUMMARY OF THE INVENTION
The present invention involves improved laser dye compositions which are superior to previously used dyes in a variety of ways. Primarily, the dyes described herein have reduced T-T absorption and a lower laser action threshold. This enables the use of flashlamps with slower risetimes. These flashlamps have a longer functional life because they operate at lower driving voltages. Furthermore, a more efficient conversion of the flashlamp pump light due to reduced T-T absorption enables the production of a higher intensity laser beam. Finally, the dyes described herein have improved photochemical stabilities which result in reduced degradation of the dye materials.
In accordance with the foregoing objects, a new group of organic materials having a wide variety of uses is disclosed. The materials are especially useful as dye compounds in dye laser systems, and as photochemical cytotoxic agents in the treatment of diseased tissues using photodynamic therapy techniques. The materials described herein involve a substituted tricyclic compound having the following structures:
(a)
Figure imgf000007_0001
wherein
R1 is selected from the group consisting of C, N, B, preferably C and N, most preferably C;
R2, R3, R5, R6, R8, R9, R1 1, and R12 are independently selected from the group consisting of C and N, wherein R6 and R8 are preferably N, and R2, R3, R5, R9, R1 1 and R12 are preferably C;
R4 and R10 are independently selected from the group consisting of C, N, O, and S, preferably C;
R7 is selected from the group consisting of C, N, B, preferably B;
R13-R19 are selected from the group consisting of H, F, Cl, Br, I, CN, NC, NO, NO2, NH2, NCO, CO2H, CONH2, phenyl, naphthyl, pyrryl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, ArF, ArN2, and NHCOAr where Ar = phenyl or naphthyl, CnH2n+ 1, where n is an integer from 1 to 4, preferably 2 to 4, Cn F2n+ 1, CnH2nF2n+ 1, (CnF2n+ 1)CO, CO2C2F2n+ 1, (CH2)nF, (CH2)nCl, (CH2)nBr, (CH2)nI, (CH2)nCN, (CH2)nNC, (CH2)nNO2, (CH2)nNO, (CH2)nCO(C nF2n+ 1), (CH2)nCO2H, and (CH2)nNH2, where n is an integer from 1 to 3, SO3M and CO2M where M is Na or K, cyclic alkyl groups having the formula CnH2n-1 where n is an integer from 4 to 6, CnH2n-2 and olefin derivatives having the formula Cn H2n-1 where n is an integer from 2 to 4, RCO, CO2R, CONHR, CON(R) 2, NHR, N(R)2, NHCOR, C(NOR)R, SO3R, SO2R, PO3R, (CH2)nCOR, (CH2)nSO3R, (CH2)nSO2R, (CH2)nNHR, (CH2)nN(R)2, and (CH2)nNHCOR where R = CnH2n+ 1 and n is an integer from 1 to 4, CnH2n-m where n is an integer from 2 to 4 and m is an integer from 2 to 4, (CH2)nAr, (CH2)nArN2, and (CH2)nNHCOAr where Ar = phenyl or naphthyl and n is an integer from 1 to 4, (CH2)nHet where Het = pyrryl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl and n is an integer from 1 to 3, and (CH2)nSO3M where M = Na or K and n is an integer from 1 to 4;
R20 and R21 are independently selected from the group consisting of H, F, phenyl, naphthyl, and Cn H2n+ 1 where n is an integer from 1 to 4, and R20 and R21 are preferably F; and
wherein R13, R14, R14, R17 and R18 are all preferably lower t-alkyl or n-alkyl, most preferably methyl or ethyl, and R16 and R19 may also be lower t-alkyl or n-alkyl, and R1-R21 can be any subgroup of the listed substituents.
(b)
Figure imgf000008_0001
wherein R22-R25 are lower t-alkyl or n-alkyl, preferably ethyl and/or t-butyl/n-butyl.
(c)
Figure imgf000009_0001
wherein R26-R29 are H or lower t-alkyl or n-alkyl, preferably lower n-alkyl, and wherein X = CH or N, or C substituted (for example with an alkyl substitution) preferably CH; and Y = CH or N or C substituted (for example with an alkyl substitution), preferably CH; or (d)
Figure imgf000009_0002
wherein R = lower t-alkyl or n-alkyl or CN; W = lower t-alkyl or n-alkyl or CN; Y = lower t- alkyl or n-alkyl or CH = CHCN; and Z = lower t-alkyl or n-alkyl or CH = CHCN.
Particularly preferred compounds include (b), (c) or (d), or any combination thereof.
Especially preferred embodiments include
Figure imgf000010_0002
and
Figure imgf000010_0001
wherein X is lower alkyl or sulfonate (or pharmaceutically acceptable sulfate salts), or more preferably lower t-alkyl or n-alkyl, and Y is lower alkyl, more preferably lower t-alkyl or n- alkyl, for example methyl, ethyl, propyl or butyl.
Examples of other compounds that can be used in the method of the present invention are those already disclosed in U.S. Patent Application Serial No. 07/513,059, which is incorporated by reference:
Figure imgf000011_0001
Using the method of the present invention, cytotoxic injury is induced in targeted tissue by introducing the compound into or adjacent the targeted tissue. After the compound is administered, the targeted tissue is exposed to a sufficient amount of light of a sufficient wavelength for a sufficient period of time to cause injury to the targeted tissue. The compound may be administered to the subject by systemic (for example, intravenous) administration, local injection into the target tissue, or topical application to the target tissue. The targeted tissue may be exposed to a light source such as a laser, a sun lamp, or a fiber optic illumination system, such as an endoscope.
These and other objects, features, and advantages of the invention will be described below in the following detailed description of preferred embodiments and accompanying examples.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph of laser energy output as a function of energy for several compounds of the invention (4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s -indacene and the disodium salt of 4,4-difluoro-1,3,5,7,&entamethyl-4-bora-3a,4a-diaza- s-indacene-2,6 disulfonic acid monohydrate) in comparison with previously known laser dyes (Rhodamine 6G and Coumarin 545).
FIG. 2 is a graph representing the absorption and fluorescence spectra of a compound of the invention (4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene) dissolved in ethanol. FIG. 3 is a bar graph showing the percentage inhibition of growth of human ovarian tumor cells in vitro following treatment of the cells with a compound of the present invention and exposure to light.
DETAILED DESCRIPTION OF SEVERAL PREFERRED EMBODIMENTS
In accordance with the present invention, improved chemical compounds and compositions are disclosed which have a variety of uses. They are especially useful as dye media in laser systems, and as photochemical agents in photodynamic therapy techniques. In dye laser systems, many of the compounds have a power output, photostability and solubility that is superior to currently available dyes, including coumarin and rhodamine-based compositions. When used in photodynamic therapy techniques, they are highly effective in destroying targeted tissues.
The basic chemical tri-cyclic structure of one class of the compositions described herein is as follows:
Figure imgf000012_0001
wherein preferred substituents are those listed in the Summary of the Invention. Several specific examples of these compounds are given in Examples I-III.
EXAMPLE I
In this example, the tricyclic structure shown above has the following substitution pattern:
R1-R5=C R13-R15=CH3
R6=R8=N
R7 =B R 17-R18 = CH3
R9- R 12 =C
R16=R19=H R20-R21 = F
Figure imgf000013_0002
(4,4-difluoro- 1,3,5,7, 8-pentamethyl 4-bora-3a, 4a-diaza-s-indacene).
To prepare this material, 2,4 dimethylpyrrole (2 g, 0.021 moles) was combined with freshly distilled acetyl chloride (18 ml) which was added drop-wise. This initial reaction and its intermediate product is shown as follows:
Figure imgf000013_0001
The above reaction was exothermic, and resulted in the production of a chemical mixture having a dark red color. The mixture was then heated under reflux for approximately 2 hours, followed by distillation and removal of excess acetyl chloride. The residue was treated with pentane, stirred for approximately 10 minutes at room temperature, and pentane was decanted. The residue was triturated with pentane (approximately 50 ml) for about 1 hour. A black, finely divided solid was removed, washed with approximately 10 ml of pentane, dried in air, and then dried in a desiccator under vacuum for about 2 hours. This material, which represents the intermediate product of the above reaction (pentamethylpyrromethene hydrochloride), weighed approximately 2.5 grams and had a melting point of 180-182°C.
Next, the pentamethylpyrromethene hydrochloride (2.5 grams, 0.01 moles) was dissolved in 350 ml of benzene. Triethyl amine (9.6 grams, 0.095 moles) was then added to the dissolved pentamethylpyrromethene hydrochloride, and the mixture stirred at room
temperature for about 10 minutes. The reaction flask containing these materials was subsequently purged with nitrogen. Boron trifluoride etherate (16 ml, 0.13 N) was added drop- wise over a period of 5 minutes. The mixture was heated under reflux for about 20 minutes, allowed to cool to room temperature, washed with three 100 ml portions of water, and dried over magnesium sulfate. The brownish-red solid product was purified by flash column chromatography over silica eluted with 60:40 benzene/pentane. This resulted in green-yellow fluorescent fractions which were subsequently combined and concentrated to a reddish-orange solid (2.1 grams). The solid recrystallized from ethyl acetate to give 1.7 grams of product (4,4- difluoro-1, 3,5,7, 8-pentamethyl-4-bora-3a,4a-diaza-s-indacene [C14H17BF2N2] m.p. = 255- 257°C). A schematic summary of the manufacturing steps used to produce the product from pentamethylpyrromethene hydrochloride is illustrated in the following reaction:
Figure imgf000014_0001
The foregoing procedure resulted in a 69 % product yield. With respect to use of the product as a laser dye, it has a lasing threshold of 9.5 kV, with a lasing wavelength range of approximately 532-565 nm. This data was obtained using a 60 mg quantity of product dissolved in 250 ml of methanol in a 10 mm flashlamp D-1100 dye laser manufactured by the Phas-R Company of New Durham, New Hampshire (Model D-1100).
FIG. 2 shows the absorption (S-S) and fluorescence (FL) spectra of the compound of Example I (designated PMP-BF2) dissolved in ethanol. The T-T absorption spectrum was recorded at 77K, employing a 1 x 10-4 molar solution of 2-methyltetrahydrofuran as solvent.
In addition, tests were conducted on the product in order to determine its solubility/fluorescence in various solvents. One property of the compositions described herein involves a variable degree of solubility/fluorescence relative to the solvents with which they are combined. Data showing a variety of different solvents combined with the product of Example I is presented below in Table I:
Figure imgf000015_0001
In addition, experiments were conducted in order to determine the photostability of the product of Example I. A solution was prepared by mixing 0.1 g of the product with 50 ml of dichloromethane solvent. The solution was placed in a 100 ml round bottom flask and irradiated with light from a sun lamp (250 watts at a distance of approximately 8 inches from the flask). No visual change in fluorescence was observed over a period of 22 days. However, another solution was made by combining 0.1 g of product in 250 ml of CH3OH and 10 ml of CH2Cl2. Addition of the CH2Cl2 was undertaken to obtain complete dissolution. The solution was placed in a 250 ml round bottom flask and irradiated as described above. After 8 days, no fluorescence was observed. Thus, the use of different solvents will cause a variation in both the character and duration of fluorescence.
EXAMPLE II
In this example, the tricyclic structure given above has the same substitutions as in Example I, but R16=R19=SO3 -2 (as SO3Na).
Figure imgf000016_0001
(Disodium salt of 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene-2,6- disulfonic acid monohydrate).
To prepare this compound, 0.5 g (0.002 moles) of 4,4-difluoro-1,3,5,7,8- pentamethyl-4-bora-3a,4a-diaza- s-indacene (prepared as described above in Example I) were combined with 20 ml of methylene chloride. The mixture of these materials (maintained at - 10ºC) was combined with a solution of chlorosulfonic acid (0.24 ml, 0.004 moles) added drop-wise using a syringe. The mixture was stirred at -10ºC for approximately 0.5 hours and allowed to reach room temperature over a period of 1 hour. A suspended yellow solid was isolated by filtration, dissolved in 75 ml water and the solution was neutralized with sodium bicarbonate (0.30 grams). Sodium bicarbonate was continuously added thereafter until effervescence stopped. The aqueous solution was concentrated to approximately one-quarter its previous volume. Upon the addition of about 15 ml of ethanol, a yellow precipitate appeared which was isolated and dried in a desiccator under vacuum. The precipitate weighed approximately 0.66 grams, had a melting point of about 260°C, and represented the final product (the sodium salt of 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s- indacene-2,6-disulfonic acid monohydrate-[C 14H15BF2N2O6S2Na2.H2O]). Production of this product is shown in the following basic reaction:
Figure imgf000017_0001
With respect to its use as a laser dye, the product had a lasing threshold of 10 kV with a lasing wavelength range of 545-585nm. This data was obtained using a 60 mg quantity of product dissolved in 230 ml of H2O in a 10 mm flashlamp dye laser manufactured by the Phas-R Company (Model D-1100).
As in Example I, tests were conducted on the product in Example II in order to determine its fluorescence in various solvents. Data showing a variety of different solvents combined with the product of Example II is presented below in Table II:
Figure imgf000018_0001
In addition, a further test was conducted in order to determine the photostability of the product. Specifically, 2.0 mg of the product in a 100 ml round bottom flask was dissolved in 50 ml of H2O. The solution was then irradiated by light from a 250 watt sun lamp placed approximately 8 inches from the flask. UV spectral data was recorded periodically as shown below in Table III.
Figure imgf000019_0001
In addition to the two compounds described above in Examples I and II, the following is another preferred compound.
EXAMPLE III
The tricyclic structure of this Example has the following substitution pattern:
R1 = C R12 = CH
R2 = C R13 = CH3
R3 =C R14 = CH2CH3
R4 = C R15 = CH3
R5 =C R16 = H
R6 =N R17 = CH3
R7 = B R18 = CH3
R8 =N R19 = H
R9 = C R20 = F
R10 = C R21 =F
R11=C
Figure imgf000020_0001
(4,4-difluoro-1,3,5,7-tetramethyl-8-ethyl-4-bora-3a,4a-diaza-s-indacene).
Table IV below summarizes the basic characteristics of the compounds of
Examples I, II and III in comparison with a previously known compound (Rhodamine 590).
TABLE IV
Laser Characteristics of Pyrromethene-BF 2 Complexes
Under Flashlamp Excitation
Figure imgf000020_0002
* After 1000 S at 25 J, Eo ~80 mJ
In addition, FIG. 1 shows the laser output E (in mJoule) as a function of input energy E (in Joule) of a 1.5 x 10-4 molar solution of the compound of Example I (designated PMP-BF2) dissolved in ethanol, a 2 x 10-4 molar solution of Coumarin 545 dissolved in ethanol, a 2 x 10-4 molar solution of Rhodamine 6G dissolved in ethanol, and a 2 x 10-4 molar solution of the compound of Example II (designated PMP-BF2-sulfonate) dissolved in ethanol. EXAMPLE IV
Under synchronous pumping by a mode-locked Coherent Antares Nd:YAG laser, the dye 1,3,5,7,8-pentamethyl-2,6-diethylpyrromethene-BF2 complex (PMDEP-BF 2) gave twice the power output efficiency obtained from R-6G. PMDEP-BF 2 showed a photostability lifetime of 500 W-hrs.
Figure imgf000021_0001
Similar results from tests in a Candela LFRDL 20 linear flashlamp dye laser showed the dye PMDEP-BF 2 to have 173 % of the power efficiency of R-6G. In a similar manner the disodium salt of 1,3,5,7, 8-pentamethylpyrromethene-2,6-disulfonicacid-BF2 complex (PMPDS-BF 2) showed 145% of the power efficiency obtained from R-6G in a
Candela LFDL-8 laser with flashlamp excitation, at a pulsewidth of 2 μsec, and a risetime 0.7 μsec.
In a continuous wave (CW) operation with an argon ion pump laser (5 watts all lines 457.9-514.5nm) PMPDS-BF , gave 45 % power efficiency and PMDEP-BF 2 gave 37%, whereas R-6G delivered a power output at 32%.
Under flashlamp excitation pulses the photostability in methanol of PMPDS- BF2 (9000 pulses) was six times greater than that for R-6G (1500 pulses).
In a technological breakthrough P-BF2 dyes homogeneously dispersed in an acrylic co-polymer were found to be superior "solid-state" lasers with the special feature of tunability characteristic of a laser dye. PMDEP-BF 2 (10-4M) in a polymer matrix (5 parts methyl methacrylate and 1 part hydroxypropyl acrylate) gave a power efficiency of 88%. R- 6G under similar treatment gave an unsatisfactory performance and was not measured; sulforhodamine-B gave a 37% efficiency. Similar tests showed other P-BF2 dyes to rival and/or to surpass PMDEP-BF 2 in efficiency. The PMDEP-BF 2 and PMPDS were found to be particularly soluble in the polymer matrix.
The polymer matrix is disclosed in U.S. Patent No. 5,136,005which is incorporated by reference. Any laser dye of the present invention may be substituted for the dye in any of the examples of that incorporated patent. The matrix generally includes solid polymeric host laser rods prepared using bulk polymerization of acrylic acid ester comonomers. When the polymer is admixed with dyes capable of supporting laser oscillation and poiymerized with a free radical initiator under mild thermal conditions, a solid product is produced having efficient lasmg properties. Several dyes of the present mvention have been found to have superior solubility in these polymer matrices, which in turn increases the efficiency of lasing action.
In a typical measurement of the P-BF2 chromophore triplet-tri plet (T-T) absorption for the dye PMPDS-BF2 was barely detectable ( 6T ~3 x 10-3) in the fluorescent spectral area.
These results made P-BF2 dyes very suitable for performance m any situation where tunable lasmg activity in the range 520-600 nm is called for.
LASER ACTIVITY
In the spectral region from 300 to 1300 nm, two groups of dye molecules have particularly been noted to have laser dye activity. The group of fused lmear 6,6,6-tricyclic ring systems contains the dye rhodamine 6G (R - 6G) 1.
Figure imgf000022_0001
C6H4CO2C2H5-o
(1)
This laser dye had the highest power efficiency from flash lamp pumping known at the time of its discovery. In another group the cyanine dyes 2 were recognized for the ability of their luminophors in providing laser activity in the longer wavelengths, particularly > 800 nm.
Figure imgf000022_0002
RN - ( CH=CH- ) mC=CH ( CH=CH- ) nC= ( CH-CH) =) mN+RX-
(2)
R is a substituent such as alkyl, X is an anion, m = 0 or 1, and n = 0-5.
A bathochromic shift of about 100 nm with each unit increase in n, the number of conjugated ethylenic units in the odd numbered carbon chain connectmg two heterocychc nuclei in the monobasic salt, brought about a distribution of absorption, fluorescence, and laser activity over a wide spectral region. Structures 3a, λlas 541 nm, and 3b, λlas 800 nm, are typical cyanine dyes.
Figure imgf000023_0001
3a n = 1. R = C2H5
3b n=3. R = CH3
(3)
Tables I and II illustrate some of the compounds that will be discussed in the following sections
Figure imgf000023_0002
Figure imgf000024_0001
The invention includes any combination of the compounds in Table II, or any
subcombinations thereof.
Compounds 7h and 7i each have a four carbon bridge -(CH2)4- as substituents Y and Z. Compound 7j has a three carbon bridge -(CH2)3- as substituents X and Y, that forms a five membered ring (see Example VII).
The P - BF2 molecules 7 uniquely blended the structural features of a cyanine dye 2, n = 3, and a planar fused tricyclic ring system and introduced laser dyes with a linear 5,6,5-tricyclicring system. The parent linear 5,6,5-tricyclicantiaromatic (4n π e) hydrocarbon, s-indacene C12H8 was a red solid but was not described as fluorescent. In contrast the parent 6,6,6-tricyclicaromatic (4n + 2π e) hydrocarbon, anthracene C14H10, showed λf 400 nm.
Although pyrromethene salts also met the structural requirement of a cyanine dye with n = 3, such salts were weakly fluorescent. For example, 3,3',5,5'-tetramethyl-4,4'- diethylpyrromethene hydrobromide 9 (Table III) showed Φf 4.3 x 10-4.
Figure imgf000025_0001
Conversion to boron complexes, such as
1,3,5,7-tetramethyl-2,6-diethylpyrromethene-B(CH2CH3)2 complex 10 ( Φf 0.31) and the corresponding BF2 complex 11 ( Φf 0.81) raised the fluorescence quantum yield by a thousand fold. In addition laser activity 550 to 570 nm became a characteristic property of P- BF2 7. This property qualified P - BF2 compounds as bridged cyanine dyes, n = 3, with the particular feature of a hypsochromic shift of over 200 nm from λlas 800 nm observed for a linear cyanine dye 3b, n = 3.
A general synthesis scheme of the compounds in Table II is described in the following section, with reference to the compounds in Table I.
A Knorr cyclization between ethyl a - aminoacetoacetate (prepared in situ) and a 3-alkyl-2,4-pentandione was selected for the preparation of ethyl alkylpyrrole-2 - carboxylate derivatives 4b- f, i. Ethyl 3,5-dimethyl-4-tertbutylpyrrole-2-carboxylate 4g was prepared from ethyl 3,5-dimethylpyrrole-2-carboxylate 4a in an alkylation with tert-butyl acetate. In a modification of a Knoevenagel condensation of ethyl N-(3-oxo-1-alkenyl)aminoacetates to ethylpyrrole- 2-carboxylates ethyl 3-methyl-2,4,-5,6- tetrahydrocyclopenta[c]pyrrolecarboxylate 4j was obtained by a base catalyzed cyclization of an unisolated enam ine 13 (Table IV), in turn obtained from a condensation between glycine ethyl ester and ot-acetylcyclopentanone.
Figure imgf000026_0001
Conversion of α-pyrrolecarboxylate esters to α-unsubstituted pyrroles by treatment with
phosphoric acid provided a convenient preparation of pyrrole 5b and was extended to
3-n-propyl, 3-n-butyl, and 3-isopropyl derivatives 5d-f of 2,4-dimethylpyrrole 5a. A similar conversion afforded 3-methyl-4,5,6,7-tetrahydroindole 5i from its 2-carboxylate ester derivative 4i. Unsuccessful attempts to extend the method to the preparation of
2,4-dimethyl-3-tert-butylpyrrole 5g led instead to the replacement of both the carboethoxy and tert-butyl groups with hydrogen to give 2,4-dimethylpyrrole 5a. The pyrroles 5g, j, k were obtained from ethyl 3,5-dimethyl-4-tert-butylpyrrole-2-carboxylate 4g, ethyl
3-methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrrolecarboxylate 4j, and ethyl
3,4-diethyl-5-methylpyrrole-2-carboxylate 4k by saponification with potassium hydroxide
followed by decarboxylation of the free acids in ethanolamine at 180°C.
Synthesis of Pyrromethene - BF2 Complexes (P- BF2)
Treatment with an acyl chloride converted pyrroles 5 (Table I) to P - BF2 7
(Table II) via unstable and generally unisolated pyrromethene hydrochlorides 6.
Kryptopyrrole 5c and acetyl chloride gave the isolated but unstable
3,5,3',5',6-pentamethyl-2,6-diethylpyrromethenehydrochloride 6c. It was subsequently
determined that conversion of the unstable intermediate 6c without isolation to PMDEP - BF2 7c by treatment with boron trifluoride etherate was recommended and became the basis for a general procedure for conversions of other pyrroles to P - BF2. Derivatives of
2,4-dimethylpyrrole with 3-substituents (n-propyl 5d, n-butyl 5e, isopropyl 5f, tert-butyl 5g, phenyl 51, and acetamido 5m) gave the corresponding 2,6-disubstituted derivatives 7d-g, 1, m of 1,3,5,7,8-pentamethylpyrromethene - BF2 complex (PMP - BF2) 7a. Similar treatment with acetyl chloride converted tetrahydroindole 5h, 3-methyltetrahydroindole 5i,
3-methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrrole 5j, and 3,4-diethyl-5-methylpyrrole 5k to t 2,3,6,7-bistetramethylene-8-methylpyrromethene - BF2 complex 7h, its 1,7-dimethyl derivative 7i, 1,2,6,7-bistrimethylene-3,5,8-trimethylpyrromethene - BF2 complex 7j, and
1,2,6,7-tetraethyl-3,5,8-trimethylpyrromethene BF2 complex 7k and converted
2,3-dimethyl-4-methoxypyrrole 5n to 1,7-dimethoxy- 2,3,5,6, 8-pentamethylpyrromethene - BF2 complex 7n.
Kryptopyrrole 5c condensed with propionyl chloride, isobutyryl chloride, cyclohexanecarbonyl chloride, acetoxyacetyl chloride, and p - dimethylaminobenzoyl chloride to produce the 8-ethyl, 8-isopropyl, 8-cyclohexyl, 8-acetoxy methyl, and 8-dimethylaminophenyl derivatives 7o-s of 1,3,5,7-tetramethyl-2,6-diethylpyrromethene - BF2 complex. A
straightforward extension of the procedure was found in the reaction between 2,4- dimethylpyrrole 5a and p-anisoyl chloride to give l,3,5,7-tetramethyl-8p- methoxyphenylpyrromethene - BF2 complex 7t via the intermediacy of the otherwise uncharacterized pyrromethene hydrochloride 6t. Attempts to convert 2-trifluoroacetyl- 3,5-dimethylpyrrole 12 to a derivative of 8-trifluoromethylpyrromethene - BF2 complex were unsuccessful.
Treatment with hydrobromic acid in formic acid brought about the conversion of α-pyrrolecarboxylate esters 4 to pyrromethene hydrobromides 6 via the presumed intermediacy of α-unsubstituted pyrroles 5 followed by condensations with formyl derivatives formed in situ. Thus the esters 4k, o, p afforded the pyrromethene salts 6y, 6u, and 6v respectively. Straightforward treatment with boron trifluoride etherate converted these crude pyrromethene hydrobromides to 1,2, 6, 7-tetraethyl-3, 5-dimethylpyrromethene - BF2 complex 7y, and the 1,7-diphenyl-2,6-diethyl-3,5dimethyl and
1,2,6,7-tetraphenyl-3,5-dimethylpyrromethene - BF2 derivatives 7u, v.
Similar treatment converted 3,3'-diphenyl-4 ,4-diacetyl-5,5'- dimethylpyr- romethene hydrobromide 14 (from ethyl 3-phenyl-4-acetyl-5- methylpyrrole-2 carboxylate 4q) after an initial deacetylation to
1,7-diphenyl-3,5-dimethylpyrromethene - BF2 complex 7w. An assumed unisolated pyrromethene hydrobromide intermediate 6x from the pyrrolecarboxylate ester 4g was converted to 1,3,5,7-tetramethyl-2,6-di- tert-butylpyrromethene - BF2 complex 7x.
Addition of hydrogen cyanide to the pyrromethene hydrobromide 9 presumably brought about the formation of 3,5,3',5- tetramethyl-4,4'-diethyl-6-cyanopyrromethane 15. Dehydrogenation by bromine followed by treatment with boron trifluoride etherate converted the pyrromethane 15 to
1,3,5,7-tetramethyl-2,6-diethyl-8-cyanopyrromethene - BF2 complex 7bb via the corresponding pyrromethene hydrobromide 6bb. LASER ACTIVITY
Variation in similar pairs of 2,6-dialkyl substituents in derivatives 7b-g of PMP - BF2 7a was carried out to demonstrate which dyes were competitive with PMDFP - BF2 7c in laser activity. As the pairs of similar 2,6-disubstituents changed from hydrogen to methyl, ethyl, n-propyl, n-butyl, and isopropyl in dyes 7a-f the electronic absorption shifted from λmax 493 nm to 517 ± 1 nm with a nearly constant log ε 4.8 + 0.1. A significantly larger bathochromic shift led to λmax 525. log ε 4.83, for the 2,6- di-tert-butyl derivative 7g, Table 1.
Laser activity λlas was previously reported for PMP - BF2 7a at 542 nm and for PMDEP - BF2 7c at 570 nm in Shah et al., Heteratom. Chem. 1:389, 1990. Similar activity was found in the 2,6-dimethyl, 2,6 di-n-propyl, 2,6-di-n-butyl, and 2,6-diisopropyl derivatives 7b, d-f at 573, 578, 580, and 577 nm and in the 2,6-di-tert -butyl derivative 7g at 597 nm. In partial fulfillment of the factors contributing to laser activity each of these seven dyes showed high extinction coefficients log e 4.8 to 4.9 and high fluorescence quantum yields Φf 0.67 to 0.99. PMP - BF2 7a, PMDEP - BF2 7c, and the 2,6-di-n-butyl derivative 7e were superior to the other four 2,6 - dialkyl derivatives in laser activity RE (relative efficiency in power output where RE 100 is arbitrarily assigned to rhodamine -6G).
The data revealed an alternation in RE as the 2,6-di-n-alkyl substituents contained an odd number of carbon atoms 7b, d (RE 65, 85) or zero and an even number of carbon atoms 7a, c, e, RE ≥ 100, Table VI. Although the bistetramethylene dyes 7h, i and the bistrimethylene dye 7j gave nearly identical λmax with high extinction coefficients log ε > 4.8 and shared strong fluorescence Φf ≥ 0.8 they differed significantly in laser activity with RE ≥ 75 for the bistetramethylene dyes and RE 20 for the bistrimethylene dye, Table VI. The structure for the dye 7j was confirmed by an X-ray crystallographic analysis to have chromophore planarity with negligible strain. Hence compounds 7 are preferred wherein Y is n-alkyl or t-alkyl containing an even number of carbons, especially 2 or 4 carbons.
Alkyl and other group substituent effects at the 8- position in 1,3,5,7-tetrame- thyl-2,6-dialkylpyrromethene - BF2 complex structures were examined. In comparison with peralkylated structures (7b, g, k) corresponding examples lacking a substituent at the 8- position (7z, x, y) showed a slight bathochromic shift in absorption, an erratic effect on fluorescence, and a marked decrease in laser activity RE, Table VI. Presumably non planarity for 1,3,5,7-tetramethyl-2,6-diethyl-8-isopropylρyrromethene - BF2 complex 7p was brought about by a steric interaction between the isopropyl group and the 1,7-dimethyl substituents and led to the large reduction in fluorescence and the loss of laser activity. A similar steric effect was introduced by the replacement of the 8-ethyl substituent in
1,3,5,7-tetramethyl-2,6,8- triethylpyrromethene - BF2 complex 7o Φ 0.84 with 8-cyclohexyl to bring about reduction in the fluorescence quantum yield to Φ 0.23 and no laser activity for the dye
1,3,5,7-tetramethyl-2,6diethyl-8-cyclohexylpyrromethene - BF2 complex 7q. Insofar as laser dyes with cyano substituents are unusual, the laser activity in diethyl
1,3,5,7-tetramethyl-8-cyanopyrromethene-2.6-dicarboxylate - BF2 complex 7aa and
1,3,5,7-tetramethyl-2,6-diethyl-8-cyanopyrromethene - BF2 complex 7bb presented exceptional interest. Four cyano substituted laser dyes were listed by Maeda in Laser Dyes, Academic Press, Tokyo, Japan, 1984, pp. 19-21.
Pairs of similar functional group (polar) substituents in the 2,6- positions of P - BF2 dyes brought about erratic results in RE. Fluorescence and laser activity were reduced in a P - BF2 dye by a nitro substituent and quenched by a bromo substituent. Metal and ammonium salts of 1,3,5,7,8-pentamethylpyrromethene-2,6-disulfonic acid - BF2 complex 16 (Table V) were exceptionally powerful dyes with RE 95 but the sodium salt of
1,3,5,7-tetramethyl-8-ethylpyrromethene-2,6-disulfonic acid - BF2 complex 17 showed RE 50. Low values were also obtained for the disulfonate ester 18 RE 35, the dicarboxylate ester 19 RE 50, the 2,6-diacetamido derivative 7m RE 5 and the 2,6-diphenyl derivative 71 RE 20. The singular example of 1,7-dimethoxy-2,3,5,6,8-pentamethylpyrromethene - BF2 complex 7n RE 30 suggested that laser activity was diminished by electron donating substituents at the
1,7- positions. Low lasing activity resulted from the introduction of phenyl substituents in the 1- and 2- positions in dyes 71, 7u, and 7w and the absence of lasing activity was noted for 1,2,6,7-tetraphenyl-3,5-dimethylpyrromethene - BF2 complex 7v.
Figure imgf000029_0001
Spectroscopic Measurements
Instruments for spectroscopic measurements included: Perkin-Elmer 1600
FTIR, Varian Gemini 300 NMR, Hewlett-Packard 5985 (70 eV) GC-MS, Cary 17 (UV), and Perkin-Elmer LS-5B Luminescence spectrometer. A dye laser was constructed and operated in the non-flowing (static) mode and had no tuning capability. The dye cell (2.5 mm diameter, 50 mm long) had an elliptical cavity configuration of small eccentricity. The flashlamp EG & G model FX 139C-2 produced a pulse that had a rise time of 200 ns, half-width length of 600 ns, and input energy of 2 J at 6.32 kV, 5 J at 10.00 kV, 7.2 J at 12.00 kV, and 10 J at 14.14kV. Laser energy outputs were measured with an accuracy of ± 5 % by a Scientech 365 power and energy meter. Light absorption, luminescence, and laser activity properties for the dyes 7 are described in Table VI. Each recorded UV absorption was restricted to the highest wave length. Fluorescence quantum yields of the dyes were determined for ethanol solutions with excitation at 450 and 460 nm by reference to acridine orange, Φ 0.46, in ethanol; for the dye 7p the reference was R-6G, <P 0.90. Table VII lists yield, mp, 1H NMR, and elemental analysis for the laser dyes 7. Melting points were obtained from a Mel -Temp II device and were uncorrected. The solvent for 1H NMR spectra was chloroform-d with tetramethylsilane as an internal standard. Elemental analyses were obtained from Midwest Micro Lab, Indianapolis, Indiana and Galbraith Laboratories, Inc., Knoxville. Tenn. Solvents were removed by rotary evaporation under reduced pressure unless indicated otherwise. Column chromatography was performed on silica gel. Molecular weights were confirmed by EI-MS for the pyrrole 4j 193 and for laser dyes 7d 346, 7e 374, 7g 374, 7i 342, 7j 314 and 7x 360. IR absorption data satisfactorily supported structure assignments for the laser dyes 7.
Figure imgf000031_0001
[a] 5 x 10-6 M in ethanol except where noted otherwise. [b] 2 x 10-4 M in ethanol except where noted otherwise, [c] Relative Efficiency 100 assigned to R - 6G. [d] Ref [2]. [e] 5 x 10-6 M in tniluoroethanol. [f] 2 x 10-4 M in trifluoroethanol. [g] With reference to R - 6G Φ 0.90 (K. H. Drexhage, J. Res. Nat. Bur. Std. 1976. 80A. 421). [h] No laser activity detected, [i] 2 x 10-4 M in p - dioxan. [j] Obtained from a Phase - R DL - 1100 dye laser with DL - 5Y coaxial flashiamp. [k] RE not determined.
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Other Materials
Commercially available pyrroles included ethyl 3,5-dimethylpyrrole-2-car- boxylate 4a, ethyl 3,4-diethyl -5-methylpyrrole-2-carboxylate 4k, 2,4-dimethyl 3-ethylpyrrole 5c (kryptopyrrole), and 4,5,6,7-tetrahydroindole 5h.
The following pyrroles and pyrromethene derivatives were prepared by the methods cited: ethyl 3,5-dimethyl-4-ethylρyrrole-2-carboxylate 4c (Kleinspehn, J. Amer. Chem. Soc. 77: 1546,1955), ethyl 3,4-diethyl-5-methylpyrrole-2-carboxylate 4k (Wang and Chang, Synthesis, p. 548, 1979), ethyl 3-phenyl-4-ethyl-5 methylpyrrole-2-carboxylate 4o (Ogoshi et al., Tetrahedron Lett. 24:929, 1983); Guy and Jones, Aust. J. Chem. 19:1871, 1966), ethyl 3,4-diphenyl-5-methylpyrrole-2-carboxylate 4p (Guy and Jones, 1966), ethyl 3-phenyl- 4-acetyl-5-methylpyrrole-2-carboxylate 4q (Guy and Jones, 1966),
2,4-dimethylpyrrole 5a (Treibs and Schulze, Leibigs Ann. Chem. 739:222,225, 1970), 2,4-dimethyl-3-phenylpyrrole, 51 (Guy and Jones, 1966), 3-acetamido-2,4-dimethylρyrrole 5m (Zavyalov et al., Izv. Akad. Nauk. Ser. Khim. 1906, 1973), 3-methoxy-4,5- dimethylpyrrole 5n (Bauer, Leibigs, Ann. Chem. 736: 1, 1970),
1,2,3,5,6,7-hexamethylpyrromethene- BF2 complex 7z (Vos de Wael, Reel. Trav. Chim. Pay- Bas 96:306, 1977), diethyl 1,3,5,7-tetramethyl-8-cyanopyrromethene-2,6-dicarboxylate - BF2 complex 7aa (Treibs and Kreuzer, Liebigs Ann. Chem. 718:208, 1968), and 3,5,3',5'- tetramethyl-4,4'-diethylpyrromethene hydrobromide 9 (Johnson et al., J. Chem. Soc. 3416, 1959).
3 - n - Propyl - 2,4, - pentanedione. A mixture of iodopropane (317 g, 1.87 mol),
2,4-pentanedione (146 g, 1.51 mol) and anhydrous potassium carbonate (200 g) in dry acetone (300 ml) was heated at 60°C for 20 h, cooled, combined with petroleum ether (300 ml), and filtered. The filtrate was washed with a mixture (1: 1, 200 ml) of petroleum ether and acetone. Solvent removal left 3-n-propyl-2,4-pentanedione as a light yellow oil, 53 g (25%), bp 195°C (lit. bp 73 °C /11 mm). In a similar procedure (a) iodobutane and 2,4-pentanedione gave 3-n-butyl-2,4-pentanedione as a light yellow oil, 28%, bp 208ºC (lit. bp 104 -106°C/20 mm) and (b) isopropyl iodide and 2,4-pentanedione gave 3-isopropyl-2,4-pentanedione as a light yellow oil, 40%, bp 182°C (lit. bp 94°C/45 mm).
Ethyl 3,5-dimethyl-4-n-propylpyrrole-2-carboxylate4d. A solution of sodium nitrite (28.2 g, 0.41 mol) in water (100 ml) was added to a stirred cold solution of ethyl acetoacetate (49.4 g, 0.38 mol) in acetic acid as the temperature was held below 15 °C. After the solution was stirred and stored overnight at 25 °C, 3-n-propyl-2,4-pentanedione (53.7 g, 0.38 mol) and zinc (53 g) were sequentially added and the mixture was stored at 60°C for 1 h. Dilution with water brought about the precipitation of ethyl 3,5-dimethyl-4-n-propylpyrrole-2-carboxylate 4d as a yellow solid, 22.4 g (29%), mp 98-99°C (lit. mp 99 - 99.5°C) after recrystallization from ethanol; 1H NMR (CDCl3): δ 9.3 (s, 1H), 4.25 (q, 2H), 2.25 (t, 2H), 2.24 (s, 3H), 2.18 (s, 3H), 1.41 (m, 2H), 1.30 (t, 3H), 0.90 (t, 3H). The procedure was extended to the conversions of (a) 3-n-butyl-2,4-pentanedione to ethyl 3,5-dimethyl-4-n-butylpyrrole-2-carboxylate4e, a yellow solid, 32%, mp 99-100°C (lit. mp 99 °C), 1H NMR (CDCl3): δ 9.35 (s, 1H), 4.27 (q, 2H), 2.50(t, 2H), 2.25 (s, 3H), 2.15 (s, 3H), 1.40(m, 4H), 1.31 (t, 3H), and 0.91 (t, 3H); (b) 3-isopropyl-2,4-pentanedione to ethyl 3 ,5-dimethyl-4-isopropylpyrrole-2-carboxylate4f, 20% , mp 104-106ºC (lit. mp 105-106.5°C); and (c) 2 - acetylcyclohexanone to ethyl 3-methyl-4,5, 6,7- tetrahydroinadole-2-carboxylate4i, 50%, mp 111-113°C (lit. 110°C), 1H NMR (CDCl3): δ 9.03 (s, 1H), 4.25 (q, 2H), 2.41 (m, 4H), 2.21 (s, 3H), 1.65 (m, 4H), 1.30 (t, 3H).
Ethyl 3,5-dimethyl-4 -tert-butylpyrrole-2-carboxylate4g. A solution of acetic acid (5.0 ml), sulfuric acid (1.2 ml), ethyl 3,5-dimethylpyrrole-2-carboxylate 5a (5.0 g, 0.03 mol) and tert-butyl acetate (3.5 g, 0.03 mol) was heated at 75 °C for 2 h and combined with sodium carbonate (8 g) in ice water (100 ml) to bring about the precipitation of ethyl
3,5-dimethyl-4-tert-butylpyrrole-
2-carboxylate 4g as a colorless solid, mp 108-110°C (lit. 107-109°C), 3.1 g (47%); 1H NMR (CDCl3): δ 9.80(s, 1H), 4.28 (q, 2H), 2.43 (s, 3H), 2.39 (s, 3H), 1.35 (s, 9H), 1.33 (t, 3H).
Ethyl 3-methyl -2,4,5,6-tetrahydrocyclopenta-[c]pyrrolecarboxylate 4j. A procedure for the synthesis of pyrroles via N-(3-oxo-1-alkenyl)glycine ester was adapted from Hombrecher and Horter, Synthesis 389, 1990. Ethyl aminoacetate hydrochloride (28 g, 0.20 mol) and triethylamine (20.1 g, 0.20 mol) were added to a solution of 2-acetylcyclopentanone (25.0 g, 0.20 mol) in ethanol (400 ml). The solution was stirred at room temperature for 15 hours and concentrated. The residue was combined with water (250 ml), and extracted with methylene chloride (4 x 100 ml). The combined extract was washed with water (100 ml), dried (sodium sulfate), and concentrated to leave a light brown oil. The oil was added with stirring at 50°C to a solution of sodium ethoxide (14 g, 0.20 mol) in absolute ethanol (400 ml). The mixture was heated at 80°C for 3 hours and poured into water (500 ml) to precipitate a light yellow solid. Recrystallization from ethanol gave ethyl 3- methyl-2,4,5,6-tetrahydrocyclopenta-[c]pyrrolecarboxylate 4j, 9.1 g (24%) as a pale yellow solid, mp 166-167°C; 1H NMR (CDCl3): δ 8.38 (s, 1H), 4.24 (q, 2H), 2.78 (t, 2H), 2.52 (t, 2H), 2.30 (m, 2H), 2.18 (s, 3H), 1.30 (t, 3H). Anal, calcd for C11H15NO2: C, 68.39;H, 7.77; N, 7.25.Found, C, 68.40;H, 7.85; N, 7.15. 2 - Trifluoroacetyl - 3 ,5 - dirnethylpyrrole 12. Trifluoroacetic anhydride (15.8 g, 75 mmol) was added dropwise with stirring to a solution of 2,4-dimethylpyrrole 5a (9.6 g, 50 mmol) in benzene (140 ml) at 0 °C. The mixture was stored at 0°C for 3 h and washed with water (25 ml). The separated organic layer was dried (magnesium sulfate), concentrated, and chromatographed (silica gel, hexanelethyl acetate, 3/1) to give
2-trifluoroacetyI-3,5-dimethylpyrrole 12 as a colorless solid, mp 80°C, 10.6 g (55%); IR (KBr): v) 3309, 1630,1563,1500, 1443, 1227, 800; 1H NMR (CDCl3): δ 5.9 (s, 1H), 2.35 (bs, 6H). Anal, calcd for C8H8NOF3: C, 50.26;H, 4.18;.N, 7.32;F, 29.84.Found: C. 50.27;H, 4.28; N, 7.16; F, 29.92.
Phosphoric acid method for the conversion of ethyl pyrrole-2-carboxylatesto α -unsubstituted pyrroles. 2,4-Dimethyl-3-isopropylpyrrole5f. Ethyl 3,5-dimethyl-4-isopropylpyrrole-2 - carboxylate 4f (8.4 g, 40 mmol) as a melt at 100°C was treated with phosphoric acid (85%, 20 ml). The mixture was heated at 160ºC for 30 min and combined with aqueous sodium hydroxide (200 ml, 200 mmol). Distillation gave 175 ml that was extracted with diethyl ether (3 x 100 ml). The organic phase was dried (magnesium sulfate) and concentrated to give a dark brown oil. Distillation gave 2,4-dimethyl-3-isopropyl-pyrrole 5f as a colorless oil, 1.6 g (30%), bp 65-66°C (10 mm). IR (KBr): v 2296, 1684,1591, 1448,1094, 1H NMR (CDCl3): δ 6.4 (s, Η), 2.3 (s,3H), 2.2 (s, 3H), 1.9 (m, 1H), 1.0 (d, 6H). Anal. calc. for C9H15N: C, 78.83;H, 10.94;N, 10.21. Found: C, 78.69;H, 10.87;N, 10.12.
In similar reactions with phosphoric acid: (a) ethyl 3,5-dimethyl-4-n-ρro- pylpyrrole-2-carboxylate 4d converted to 2,4-dimethyl-3-n-propylpyrrole 5d, 54%, as a semi-solid, (lit. [32] mp 13.5°C), 1H NMR (CDCl3): δ 7.30(s, 1H), 6.25 (s, 1H), 2.40(t, 2H), 2.15 (s, 3H), 2.00 (s, 3H), 1.30 (m, 2H), 0.90 (t, 3H); (b) ethyl 3,5 - dimethyl-4-n-butylpyrrole-2-carboxylate 4e to 2,4-dimethyl-3-n-butylpyrrole 5e as an oil 48%, 1H NMR (CDCl3): δ 7.45 (s, 1H), 6.30 (s, 1H), 2.30 (t, 2H), 2.15 (s, 3H), 2.01 (s, 3H), 1.40 (m, 4H), 0.90 (t, 3H); and (c) ethyl 3-methyl-4,5,6,7-tetrahydroindole-2-carboxylate 4i to 3-methyl-4,5,6,7-tetrahydroindol(5i, 53 %, mp 55-57°C (lit. 58 °C), 1H NMR (CDCl3): δ 7.30 (s, 1H), 6.31 (s, 1H), 2.47 (m, 4H), 2.05 (s, 3H), 1.82(m, 4H).
2,4-Dimethyl-m-tert-butylpyrrole5g. A procedure reported for the decarboxylation of derivatives of pyrrole-3-carboxylic acid was adapted from Clue, J. Org. Chem. 19:266, 1954. A solution of ethyl 3,5-dimethyl-4-tert -butylpyrrole-2-carboxylate 4g (3.0 g, 0.01 mol) and potassium hydroxide (6.0 g, 0.11 mol) in ethanol (50 ml) was heated at 80°C for 4 h, combined with ice water (200 ml), and made slightly acidic by the addition of acetic acid to bring about the precipitation of crude 3,5-dimethyl-4-tert-butylpyrrole-2-carboxylic acid 4 (W = CH3, X = C(CH3)3, R = CO2H). The crude acid was combined with ethanolamine (5 g), heated at 180°C for 1 h, and diluted with ice water (100 ml) to bring about the precipitation of 2,4-dimethyl-3-tert-butylpyrrole 5g as a colorless solid, 1.6 g (79%), mp 70 - 71 °C (lit. 69 - 71 °C) after drying in a vacuum for 24 h; 1H NMR (CDCl3): δ 7.60 (br, 1H), 6.30 (s, 1H), 2.25 (s, 3H), 2.15 (s, 3H), 1.28 (s, 9H). By the phosphoric acid method the pyrrole ester 4g was converted to 2,4-dimethylpyrrole 5a. 3-Methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrrol5j. A solution of ethyl
3-methyl-2,4,5,6-tetrahydro-cyclopenta[c]pyrrolecarboxylate 4j (9.1 g, 0.04 mol) and potassium hydroxide (26 g, 0.47 mol) in ethanol (200 ml) was heated at 80°C for 4 hours and concentrated. The residue was combined with ice water (400 ml), and made slightly acidic by the addition of acetic acid to bring about the precipitation of crude 3 - methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrrolecarboxylicacid. The crude acid was combined with ethanolamine (5 g), heated at 180°C for 1 hour, and diluted with ice water (100 ml). Extraction by methylene chloride (3 x 100 ml) followed by solvent removal and distillation of a residual oil, bp 110 - 111 °C (20 mm) gave 3 - methyl 2,4,5,6-tetrahydrocyclopenta[c]pyrrole 5j, 3.6 g (64%) as a colorless oil; 1H NMR (CDCl3): δ 7.57 (s, 1H), 6.33 (s, 1 H), 2.67 (t, 2H), 2.59 (t7 2H), 2.35 (m, 2H), 2.22 (s, 3H). Anal, calcd for C8H11N: C, 79.34;H, 9.09;N, 11.59.Found: C, 79.12;H, 9.29;N, 11.60.
2,6-Din-propyl-1 ,3,5,7,8-pentamethylpyrromethene BF2 complex 7d. Acetyl chloride (8.0 ml, 0.11 mol) was added dropwise over a period of 5 min. to a solution of 2,4-dimethyl-3-n-pro- pylpyrrole 5d (7.0 g, 0.05 mol) in dichloromethane (5 ml). The reaction mixture was heated at 40°C for 1 h, cooled to 25 °C, diluted with hexane (250 ml), triturated, and decanted. The residue, presumed to be crude 3,5,3',5',6-pentamethyl-2,6-di-rpropylpyrromethene hydrochloride 6d, was treated without further purification with ethyldiisopropyl amine (45 g) (triethyl amine was also effective) in toluene (300 ml) and stirred 15 min. After boron trifluoride etherate (40.8 ml, 0.33 mol) was added dropwise with stirring the solution was heated at 40°C for 1 h, washed with water (200 ml), dried over magnesium sulfate, and concentrated to give a dark brown solid. Flash chromatographic purification (twice, silica gel, 300 g, 230-400 mesh, 60A, toluene) followed by concentration of the green-yellow fluorescent fraction gave the P - BF2 7d as a solid, 1.8 g. Further characterization and examples of similar conversions of pyrroles 5e-5n to P - BF2 derivatives 7e-7n are described in Tables VI and VII.
When acetyl chloride was replaced with propionyl chloride, isobutyryl chloride, cyclohexanecarbonyl chloride, acetoxyacetyl chloride, and p-dimethylaminobenzoyl chloride similar reaction sequences converted kryptopyrrole 5c to 8-ethyl, 8-isopropyl, 8-cyclohexyl, 8-acetoxymethyl, and 8-dimethylaminophenyl derivatives 7o-s of 1,3,5,7-tetramethyl-2,6- diethylpyrromethene - BF2 complex 7 (X = Z = CH3, Y = CH2CH3). Treatment with p-anisoyl chloride followed by boron trifluoride etherate converted 2,4-dimethylpyrrole 5a to 1,3,5,7-tetramethyl-8-p-methoxyphenylpyrromethene - BF2 complex 7t. The properties of the products 7o-t are described in Tables VI and VII.
Pyrromethene Hydrobromides and BF2 Complexes. Crude pyrromethene hydrobromides 6 were obtained from a α-pyrrole carboxylate esters 4 (Kleinspehn, 1955) and converted without purification to P - BF2 dyes 7. A mixture of ethyl 3-phenyl-4-ethyl-5-methyl- pyrrole-2-carboxylate 40 (2.57 g, 10 mmol), hydrobromic acid (3 ml, 48%) and formic acid (3.5 g) was heated at 100 °C for 4 h. The reaction mixture was cooled to 0 °C to bring about the separation of crude 3,3'-diphenyl-4,4'diethyl-5,5'-dimethylpyrromethenehydrobromide 6u 1.3 g (55%) mp 235°C (dec); ethyl 3,4-diphenyl-5methyl-pyrrole-2-carboxylate 4p gave crude 3,4,3' Atetraphenyl-5 ,5-dimethylpyrromethenehydrobromide 6v (75%) mp 280°C (dec) (lit. mp 280°C (dec)); and ethyl 3-phenyl-4-acetyl-5-methylpyrrole-2-carboxylate 4q gave crude 3,3 '- diphettyl-4,4'-diacetyl-5,5'-dimethylpyrrometheniιydrobromide 14 (50%) mp 230°C (dec). In similar conversions 3,5-dimethyl-4-tert-butylpyrrole-2-carboxylate 4g gave crude 3,5,3',5'- tetramethyl-2,6-ditert-butylpyrromethene hydrobromide 6x and ethyl
3,4-diethyl-5-methylpyrrole-2-carboxylate 4k gave crude
3,4,3',4'tetraethyl-5,5'-dimethylpyrrometherheydrobromide 6y .
Each salt 6u, v, x, y and 14 was converted by treatment with boron trifluoride etherate as described above to the corresponding P - BF2 dye 7u, v, x, y, and 7w (see Table II). Treatment of the pyrromethene hydrobromide 14 by boron trifluoride etherate also brought about deacylation. This may have occurred initially to give 3,3' diphenyl-5,5'- dimethylpyrromethene hydrobromide 6w as the precursor to the P-BF2 derivatives 7w or after an initial formation of undetected 1,7-diphenyl-2,6-diacetyl-3,5-dimethylpylrromethene - BF2 complex 7 (X = C6H5, Y = COCH3, W = H, Z= CH3).
1 ,3 ,5 ,7-Tetramethyl-2,6-diethyl-8-cyanopyrromethene BF2 complex 7bb. Ethyl
3,5-dimethyl-4-ethylpyrrole-2-carboxylate 4c was converted to
3,5,3',5'-tetramethyl-4,4'-diethylpyrromethenehydrobromide 9, mp 230-246°C (dec) by the process described above. A mixture of the pyrromethene hydrobromide 9 (7.75 g, 0.02 mol) and potassium cyanide (5.6 g, 0.084mol) in ethanol (85%, 70 ml) was heated at 80ºC with stirring for 45 min, cooled to 40°C, and diluted with water (80 ml) to bring about the precipitation of a pale brown solid. Flash chromatography on silica gel (300 g, 230 - 400 mesh, 60 A dichloromethane) gave an impure sample of 3,5,3',5'-tetramethyl-4,4'-diethyl-6 cyanopyrromethane 15, 2.5 g, 44%, mp 110-114°C, IR (KBr): v 2238 (CN). The impure pyrromethane 15 in chloroform was treated dropwise with an equimolar amount of bromine in chloroform at 25 °C over a period of 5 min. Removal of solvent left
3,5,-3,5'-tetramethyl-4,4'-diethyl-6-cyanopyrromethenehydrobromide 6bb. Without purification it was treated with boron trifluoride etherate (general procedure above) for conversion to 1,3,5,7-tetramethyl-2,6-diethyl-8-cyanopyrromethene - BF2 complex 7bb. EXAMPLE V
Figure imgf000040_0001
20
An alternation effect in the relative efficiency (RE) of laser activity in 1,3,5,7,8-pentamethyl-2,6-di-n-alkylpyrromethene-BF2 dyes 20 depended on the number of methylene units in the n-alkyl substituent, -(CH2)nH, to give RE≥ 100 when n was even (= 0, 2, 4) and RE 65, 85 when n was odd (= 1, 3) (RE 100 arbitrarily assigned to the dye rhodamine-6G).
EXAMPLE VI
Figure imgf000040_0002
7p W = (CH3)2CH
7q W = (C-C6H 11)
The absence of fluorescence and laser activity in 1,3,5,7-tetramethyl-2,6-diethyl-8- isopropylpyrromethene-BF 2 complex 7p and a markedly diminished fluorescence quantum yield ( Θ0.23) and lack of laser activity in 1,3,5,7-tetramethyl-2,6-diethyl-8- cyclohexylpyrromethene-BF2 complex 7q were attributed to molecular nonplanarity brought about by the steric interference between each of the two bulky 8-substituents with the 1,7- dimethyl substituents.
EXAMPLE VII
An atypically low RE 20 for a peralkylated dye without steric interference was observed for 1,2,6,7-bistrimethylene-3,5,8-trimethylpyrromethene-BF2 complex 7j.
Figure imgf000041_0002
Comparisons with peralkylated dyes revealed a major reduction to RE 0-40 for six dyes lacking substitution at the 8-position.
EXAMPLE VIII
Figure imgf000041_0001
7l W = X = Z = CH3, Y = C6H5
7m W = X = Z = CH3, Y = NHCOCH 3
7n W = Y = Z = CH3, X = OCH3
7aa W = CN, X = Z = CH3, Y = CO2C2H5
7bb W = CN, X = Z = CH3, Y = CH2CH3 Laser activity RE was diminished somewhat by functional group (polar) substitution in the 2,6-diphenyl derivative 71, RE 20, and the 2,6-diacetamido derivative 7m, RE 5, and in 1,7-dimethoxy-2,3,5,6,8-pentamethylpyrromethene-BF2 complex 7n, RE 30. Diethyl 1,3,5,7-tetramethyl-8-cyanopyrromethene-2,6-dicarboxylate-BF2 complex 7aa and 1,3,5,7-tetramethyl-2,6-diethyl-8-cyanopyrromethene-BF2 complex 7bb offered examples of P- BF2 dyes with electron withdrawing substituents at the 8-position. The dye 7aa, λlas 617 nm, showed nearly twice the power efficiency that was obtained from rhodamine-B, λlas 611 nm.
EXAMPLE IX
New heterocycle-BF2 dyes are needed to extend the spectral range of the P- BF2 dyes disclosed above. These above disclosed dyes have a spectral range of 520-620 nm, but it would be advantageous to broaden this range to 300-800 nm. Communication devices utilizing laser beams camouflaged by sea water, for example, require photostable, water- soluble, highly efficient blue-green dyes with laser activity near 460 nm. Photodynamic therapy for cancer is preferably performed with dyes which have luminescence near 620 nm for maximum tissue penetration. In these and other examples success depends on laser beam tunability, a feature characteristic of organic laser dyes but not generally encountered in solid state lasers. Structures for such dyes are given below, along with synthesis procedures and methods of proposed spectroscopic evaluation.
EXAMPLE X
Imidazomethene-BF 2 Complexes (I-BF2)
The tetramethyl-2,2'-biimidazole-BF2 (complex 21)
Figure imgf000042_0001
21 is related to but structurally different from the cyanines. The inventors have studied its Lewis acid salt 21-BF3, λf 377 nm Θf0.93 for laser activity. It has an observed fluorescence at 377 nm, which predicts a red shift to λf-440 nm Θf~0.9 for the more highly conjugated fluorophore in alkylated derivatives 28 of imidazomethene-BF 2 complexes (I-BF2).
A preparation for I-BF2 dyes 22
Figure imgf000043_0001
22
is outlined in Scheme 1.
Scheme 1
Figure imgf000044_0001
In part the method was adapted from a known preparation of the unsubstituted
imidazomethane (R=H). Joseph et al., Synthesis 459, 1977. The final two steps (1) oxidation by bromine and (2) chelation by treatment with boron trifluoride to give the complex 22 were adapted from a similar conversion of a pyrromethane to a pyrromethene-BF 2 complex.
EXAMPLE XI
8-Azapyrromethene-BF 2 (AP-BF2) and 8-Azaimidazomethene-
BF2(AI-BF2) Complexes
Preparation of 3,3,5,7-tetraalkyl-8-azaρyrromethene-BF2 complex 26 is outlined in Scheme 2. A condensation reaction between hydroxylamine and a λ- oxopropionitrile 24 to give an azapyrromethene 25 was reported in Stetter, Org. Syn. 59:53 (1980). The latter boron trifluoride is treated to bring about the formation of the AP-BF2 complex 26, as in the preparation of the P-BF2 complex in Shah et al., Heteroatom Chem. , 1:389, 1990.
Figure imgf000045_0002
Scheme 2
EXAMPLE XII
A somewhat different approach is proposed for the preparation of an alkylated 8-azaimidazomethene-BF 2 complex 27. The steps are outlined in Scheme 3. An alkylation of a 2-aminoimidazole by a 2-bromoimidazole gives a biimidazo-2-yl amine. Oxidation by bromine and chelation by treatment with boron trifluoride gives the AP-BF2 complex 27.
Figure imgf000045_0001
27
Scheme 3
Diρyridylamine-BF2 (DPA-BF 2) and
Dipyridylmethane-BF 2 (DPM-BF 2) Complexes.
A synthesis and characterization of α,α'-dipyridylamine-BF2 complex 29 (R =
H) was not found in the literature. Its straightforward proposed preparation by the reaction of α,α'-dipyridylamine 28 (R = H) with boron trifluoride is outlined in Scheme 4. The method may be extended to the alkylated derivatives (28 R = alkyl) of dipyridylamine.
Figure imgf000046_0002
Scheme 4
The "boratriazinium" salt (≡29, R = H) showed λlas 420, hence the alkylated DPA-BF2 derivatives 29 (R = methyl, ethyl, propyl, butyl, preferably n-alkyl) can be expected to lase at ~460 nm. This blue-green laser beam can be used for underwater communication by flashlamp dye excitation. The DPA-BF2 dye (R = H) was reported to lase following excitation by a nitrogen laser, hence dye 29 may similarly be excited by a nitrogen laser, as in Basting et al., Appl. Phys., 3:81, 1974.
A similar conversion is shown in Scheme 5, of an α ,α'-dipyridylmethane 30 by treatment with boron trifluoride to form a DPM-BF2 complex 31. These dyes are expected to fluoresce around 400-500 nm. They would be examined for response to flashlamp pulses and other means of excitation to produce laser activity.
Figure imgf000046_0001
EXAMPLE XIV
P-BF2 with Fluorescence and Laser Activity above 600 nm A red shift in the electronic spectra (absorption, fluorescence, and laser activity) of a dye molecule can be achieved by elongation of the system of conjugated double bonds in the chromophore. This elongation can be achieved by substitution in selected P-BF2 dyes.
The preparation of 1,3,5,7-tetramethyl-8-cyano-2,6-dicyanovinylpyrromethene- BF2 (complex 35) would require converting 3,5,3',5'-tetramethyl-4,4'-diiodo-6- cyanopyrromethane 33 to the corresponding 4,4'-dicyanovinylderivative 34 by treatment with acrylonitrile in the presence of palladium acetate and triphenyl phosphine in a reaction patterned after the vinylation of aryl iodides. Dieck and Heck, J. Amer. Chem. Soc., 96: 1133, 1974.
Figure imgf000047_0001
32 X = H
33 X = 1
34 X = CH=CHCN
A general procedure for halogenation of pyrroles (Chadwick, Chapter 3.05, in Katritzky and Rees, Comprehensive Heterocyclic Chemistry, 4:213, 1984) is adapted for the conversion of the pyrromethane 32 to the dibromide or the diiodide 33. Concurrent oxidation to the corresponding pyrromethene is expected to occur. The conversion of compound 34 to the P- BF2 derivative 35 will require a mild oxidative dehydrogenation of the pyrromethane to the corresponding pyrromethene followed by treatment with boron trifluoride (see Shaw et al., Heteroatom Chem. , 1:389, 1990).
Figure imgf000048_0002
Chromophore elongation is also achieved by conversions of 1,5,7,8-tetramethyl-formyl-2,6- diethylpyrromethene-BF 2 complex 36 by the Wittig reaction. March, "Advanced Organic Chemistry," 4th ed., p. 956, 1992. This versatile method is general for the conversion of aldehydes into functionalized olefins. The aldehyde 36 is treated with a Wittig ylide derived from β-bromo-propionitrile to produce 1,5,7,8-tetramethyl-3-cyanovinyl-2,6- diethylpyrromethene-BF 2 complex 37.
Figure imgf000048_0001
36 X = CHO
37 X = CH=CHCN
Fluorescence and laser activity of P-BF2 dyes 35 and 37 and similar derivatives with other conjugated unsaturated substituents at the 2,6-positions are expected near 650 nm and above.
Other specific compounds of interest comprehended in the scope of this invention include:
Figure imgf000049_0001
(2,6 - Dithia pyrromethene - BF2 complex) (2,6- Dioxapyrromethene-BF2 complex)
Figure imgf000049_0002
(Pyrromethene-metal complex)
: X = F, CnH2n+1, phenyl,
naphthyl or H
Figure imgf000049_0003
(4,4 - Dlsubstituted - pyrromethene - B - complex)
USE OF THE COMPOSITIONS AS LASER DYES
As previously indicated, the compositions described herein function efficiently as laser dyes when used with conventional dye laser systems. For example, an exemplary laser with which the compositions of the invention may be used includes a flashlamp-pumped dye laser system manufactured by the E.G. & G. Corporation (Model No. FX139C-2). This system has a flashlamp capable of producing pulses of approximately 200 ns risetime and 600 ns length at the half-width of the pulse. It is also capable of delivering 2 Joules at 6.32kV, 5 Joules at 10.0 kV, and 10 Joules at 14.14kV. The cell or containment vessel used in the system to retain the dye is about 2.5 mm in diameter and about 50 mm long.
As far as solvents for the compounds are concerned, the data in Tables I and
II is of importance. With respect to the compounds of Examples I and II, CH3OH and H2O respectively are preferred as solvents. Preferred solvents for solubilizing any of the compounds in this application may be determined by performing the solubility and fluorescence tests on them as in Tables I and II. In alternative systems, the compounds of the invention used as laser dyes may be in a gaseous form, or homogeneously dispersed in a polymer slug (e.g. a plastic such as methyl methacrylate).
Upon excitation, the compounds produce laser light having a high quantum fluorescence yield with low triplet-triplet (T-T) absorption, as well as a high degree of photostability. This improves the overall efficiency of the laser systems with which the dyes are used in comparison with previously used dye materials.
Preferred compounds for use as laser dyes which are encompassed in the scope of this invention include those compounds with a structure:
Figure imgf000050_0001
wherein the substitutions are those listed in the Summary of the Invention.
In a preferred embodiment, R1-R5 and R9-R12 = C.
In other embodiments, R 1-R 5 and R9-R12 = C and
R13 = R15 = R17 = R18 = CnH2n+ 1 where n = 1-3.
In yet other preferred embodiments, R1-R5 = R9-R12 = C; R13 = R15 = R17
= R18 = CnH2n+ 1 where n = 1-3; and R6 = R8 = N.
In more preferred embodiments, R1-R5 = R9-R12 = C; R13 = R15 = R17 = R18 = CnH2n+ 1 where n = 1-3, R6 and R8 = N and R7 = B. In yet other preferred embodiments, R1-R5 = R9-R12 = C; R13 = R15 = R17 = R18 = CnH2n+ 1 where n = 1-3; R6 = R8 = N; R7 = B; and R20 = R21 = F.
In most preferred embodiments, R 1-R 5 = R9-R12 = C; R13 = R15 = R17 = R18 = CnH2n+ 1 where n = 1-3, R6 = R8 = N; R7 = B and R20, R21 = F and R16 and R19 = H, NaSO3 or CnH2n+ 1 where n = 1-4.
EXAMPLE XV
Under synchronous pumping by a mode-locked Coherent Antares Nd: YAG laser, the dye 1,3,5,7,8-pentamethyl-2,6-diethylpyrro-methene-BF2 complex (PMDEP-BF 2) gave twice the power output efficiency obtained from rhodamine 6G. PMDEP-BF 2 showed a photostability lifetime of 500 W-hours.
Similar results from tests in a Candela LFRDL 20 linear flashlamp dye laser showed the dye PMDEP-BF 2 to have 173 % of the power efficiency of R-6G.
In a continuous wave (CW) operation with an argon ion pump laser (5 watts all lines 457.9-514.5nm) the disodium salt of 1,3,5,7,8-pentamethylpyrromethene-2,6-disulfonic acid-BF2 complex PMPDS-BF2 gave 45% power output as 32%. Under flashlamp excitation pulses the photostability in methanol of PMPDS-BF 2 (9000 pulses) was six times greater than that for R-6G (1500 pulses).
In a technological breakthrough P-BF2 dyes homogeneously dispersed in an acrylic copolymer were found to be superior "solid-state" lasers with the special feature of tunability characteristics of a laser dye. PMDEP-BF 2 (10-4 M) in a polymer matrix (5 parts methyl methacrylate and 1 part hydroxypropyl acrylate) gave a power efficiency of 88%. R- 6G under similar treatment gave an unsatisfactory performance and was not measured;
sulforhodamine-B gave a 37% efficiency. Similar tests showed other P-BF2 dyes to rival PMDEP-BF 2 in efficiency.
In a typical measurement of the P-BF2 chromophore T-T absorption for the dye PMPDS-BF2 was barely detectable ( 6T~3x10-3) in the fluorescent spectral area. PHOTODYNAMIC THERAPY
Light Source
Almost any light source can be used for photodynamic therapy. Lasers (specifically argon-pump dye lasers) can be used to produce light that is used to illuminate the targeted tissue area of the present invention. The laser is coupled to one or more fiberoptic cables to propagate light to the tip, with minimal energy loss. The tip may be cleaved for forward light projection; it may be bulb tipped for isotropic spherical distribution; or a cylindrical scattering material can be applied to the fiber tip to distribute light perpendicularly to the fiber axis. The energy delivered will depend on the dosage (the amount of light and the duration of its delivery) of light from the fiber. Before treatment, the light distribution can be calibrated at the tip with a power meter; the dosage of light delivered is preferably gauged to prevent any hyperthermic effects.
A most preferred wavelength of the light can be determined from the fluorescence (FL) spectra of the cytotoxic compounds, as in FIG. 2 for PMP-BF2. Incident light having a wavelength of about 500-550 nm produced the greatest fluorescence. That would be the most preferred wavelength for light used to illuminate PMP-BF2 in photodynamic therapy. Similar preferred wavelengths can be readily determined for the other compounds of the present invention.
Targets for Photodynamic Therapy
Photodynamic therapy (PDT) causes early, significant damage to membranes, particularly the plasma membrane, with the formation of multiple membrane blebs. These blebs protrude from the cell membrane and indicate severe membrane damage. This membrane damage is an early observable effect of the cytotoxicity induced by the method of the present invention. The term "cytotoxicity "is used in its well-known and commonly accepted medical sense to mean damage to cells. The histologic effects of tumors treated with the photodynamic therapy of the present invention characteristically exhibit an avascular necrosis. Sensitizer Dose
There is no critical dosage of drug which must be delivered to provide the cytotoxic effect of the present invention There is an expected increase in the amount of cytotoxicity as the dose of the drug increases. A preferred systemic dose of 1.5-2.5mg/kg of subject weight has been found suitable to induce cytotoxic damage in living cells following exposure to a light source, such as a sunlamp, laser, or fiberoptic scope.
Target Tissues
The photodynamic therapy of the present invention can be used to induce cytotoxic damage to many different types of living tissue. The cytotoxic damage induced by the present method occurs without respect to the tissue type, histologic characteristics, or the presence of receptors. The method is especially useful in treating patients with tumors in numerous anatomic sites, including the skin, bronchus, bladder, esophagus, brain, and gynecological and intra-abdominal tissues.
Specific examples of skin malignancies in which the cytotoxic effect of the present invention would be useful include basal and squamous cell cancers, malignant melanoma, Kaposi's sarcoma, mycosis fungoides, metatastic epidermoid, and recurrent breast cancer. Head and neck cancers that can be treated with the present method include nasopharyngeal, tongue and other oropharyngeal tumors.
Other target tissues include transitional cell carcinoma of the bladder, endobronchial cancer (such as adenocarcinoma or small cell carcinoma), esophageal cancer (such as adenocarcinoma), gynecologic tumors (such as cervical carcinoma in situ, vaginal cancer and vulvar malignancies) and even brain tumors such as glioblastoma, astrocytoma and metatastic malignancies (such as lung cancer metatastic to the brain).
Use of the Compounds in Photodynamic Therapy Testing has shown that administration of the materials to a subject, followed by excitation of a targeted tissue area using an appropriate light source can result in cytotoxic damage to or destruction of targeted tissue. Systemic intravenous introduction of the compound is preferably administered in a dosage of 1.5-2.5mg/kg of the subject's body weight, more preferably 2.0 mg/kg. Introduction of the compositions into the body of a subject is accomplished preferably by injection directly into the tumor or by topical application to the affected area. The compound is preferably provided in a 25 mg/ml sterile water solution that can be injected into the tumor or administered intravenously for systemic dosages. For topical application, a one ml amount of a 25 mg/ml or 0.3 % solution can be thinly coated on an external area of the body to be treated, and then exposed to a light source either immediately or after a few hours.
Upon IV administration, the drug spreads throughout the body and into regions of diseased tissue (e.g., cancer tissue). Thereafter, the diseased target tissue is illuminated using light from a conventional light source (e.g., laser, sun lamp, etc.). In cases of cancer wherein the neoplastic growths are relatively near the skin surface, the light is applied directly through the skin. In other cases where neoplasms are deeper within the body (e.g., in the urinary bladder, gastrointestinal tract, respiratory tract, etc.) the light would be introduced by non-surgical or surgical entry into the body. For example, if the diseased tissue is in the respiratory tract, access could be accomplished by either surgical or non- surgical entry through the mouth using a fiber optic illumination system or the like.
Activation of the compounds by illumination with an appropriate light source results in photochemical processes which destroy diseased tissues. A collimated beam of light (such as a laser) is particularly preferred because a limited area of the body (such as the tumor) can be exposed to the light without illuminating surrounding tissue.
A specific example of this procedure is described with reference to breast cancer as follows:
EXAMPLE XVI
Breast tumors were induced in fifty-day-old female Sprague Dawley rats by the oral feeding of dimethylbenzanthracene (DMBA) in peanut oil. Individual rats were fed 10 mg DMBA per 100 g body weight via gavage tubes. Palpable tumors developed 45 to 92 days after feeding. The disodium salt of 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza- s-indacene-2,6-disulfonic acid monohydrate (PMPDS-BF 2 ) was synthesized as described in Example II above. Following tumor development, tumors were measured and injected with PMPDS-BF2 dissolved in saline (x μg/ ml). PMPDS-BF 2 was injected into the center of the tumors to a concentration of 20 μg/cm3 of tumor volume.
Twenty-four hours after intratumor injection, the rats were anesthetized using phenobarbital (2mg/kg i.p.) and the injected tumors were exposed to light from either a quartz lamp (100 or 250 w) or an argon laser (with 488/514 and 628 nm frequencies) for 10- 20 minutes. Also included in this experiment were three control groups: (1) saline injected, unirradiated tumors; (2) saline injected, irradiated tumors; (3) PMPDS-BF2 injected, and unirradiated tumors. Tumor necrosis was observed in those tumors injected with PMPDS- BF2 and 50-100% tumor remission was seen in these cases. Tumors injected with PMPDS- BF2 that were not irradiated and tumors which were injected with saline solution and received irradiation showed no necrosis or remission. The data from this experiment is presented in Table VIII below.
TABLE VIII
ANTI -TUMOR ACTIVITY OF DISODIUM SALT OF
PENTAMETHYLPYRROMETHENE-2,6-DISULFONATE BORON DIFLUORIDE
(PMPDS-BF2)
(FOUR WEEKS AFTER INTRATUMOR INJECTIONS)*
Al l tumors evaluated had an ini tial total volume of 1 cm3 or less.
Figure imgf000056_0001
* Treeted once.
** Quartz lamp - 100 watt exposure for 20 min. Although not wishing to be bound by theory, applicants believe that the compounds described herein, including the product of Example II, reacts in a singlet state with tissue according to the first reaction mechanism (Type I) described above. Any of the compounds of the present invention could similarly be injected into the tumor at a dose of 2 μg/cm3 of the tumor and irradiated with the light sources of this example to induce cytotoxic injury in cells.
EXAMPLE XVII
Ovarian Cancer Cell Line
1,3,5,7,8-pentamethylpyrromethene-boron difluoride-2,6-disodium disulfonate salt (PMPDS-BF 2) and bimane diphosphonate were prepared according to previously described methods.
Human ovarian cells from fifteen individual patients were evaluated. All cancers were epithelial originating ovarian adenocarcinomas. Each cancer had been passed through at least one culture in RPMI-1640 (10% FBA) medium prior to use in the present study. In each case cells were harvested and washed in RPMI-1640 medium and resuspended in concentrations of 2.6 x 106 cells/ml at 5 °C. The cells (2.6 x 106 cells/ml) were then incubated in a RPMI-1640 growth medium (containing 10% fetal bovine albumin, penicillin 100 U/ml and streptomycin 100 μg. ml) pH, 7.4 with graded doses of PMPDS-BF 2 complex for 30 minutes at 37 °C in a 5% CO2/air incubator with gentle shaking. The three concentrations of PMPDS-BF2 evaluated in this study were 0.004 μg, 0.04 μg, and 0.4 μg/ml of medium. The cell suspension was then washed with cold RPMI-1640 medium to remove extracellular PMPDS-BF 2 complex, and then the cells were resuspended in fresh RPMI growth medium. Fifteen (15) ml portions of the cell suspensions (2.6 x 106 cells/ml) were irradiated in glass tubes at 37 ºC in room air over a 10-20 minute period using a General Electric sun lamp. Controls were cells exposed to PMPDS-BF 2 with no light exposure, cells with light exposure alone and cells with neither exposure to light nor chemicals.
Under identical conditions as above, bimane diphosphonate was evaluated for cytotoxic activities in the presence and absence of light. After the above incubations with PMPDS-BF2 or bimanes ± light as controls, melted Bacto-agar (Difco Laboratories, Inc. , Detroit, MI) was added to the cell suspensions to a final concentration of 0.3 % agar. The mixtures were plated in 35 mm plastic tissue culture dishes on a feeder layer containing an enriched McCoy's 5 A medium and 0.5% agar with the addition of 2-mercaptoethanol (5mM) and DEAE-dextran. The seeding density for the cells in this study was kept between 1-5 x 104 cells per dish and the plates incubated at 37 °C in a CO2 incubator. Incubation was continued for another 2-3 weeks and the plates examined under an inverted phase contrast microscope and cells counted. Since these cells grow as tight aggregates in soft-agar, it was impossible to determine the number of cells in each growth. Instead, an ocular micrometer was used to count colonies 30 μm or larger in size. Plating efficiency, defined as the number of colonies formed per 100 viable cells plated, was compared between groups.
These results are shown in FIG. 3. Within forty-eight (48) hours after exposure to PMPDS-BF2 (0.004 /μg/ml) plus light, the ovarian cells demonstrated pyknotic changes with nuclear fragmentation. When compared to controls, 40-70% inhibition in cell growth was observed for all cancers tested at the 0.004 μg/ml concentration. PMPDS-BF2 in concentrations of 0.4 μ g/ml of media produced 100% inhibition of cell growth for all rumors tested. PMPDS-BF2 controls in the absence of light exposure did not demonstrate significant cytotoxic responses. The bimane diphosphonate in concentrations of 0.4 μg/ml, under identical conditions to the above using PMPDS-BF 2, produced only 10-30% cell inhibition in the ovarian cancer cells studied.
Ovarian cancer cells three days post exposure to PMPDS-BF 2 (0.04 μg/ml) plus light were unable to colonize, demonstrated pyknotic changes in the nucleus and cytoplasmic discoloration. The cells retained a yellow-green color for up to four (4) weeks and failed to colonize when resuspended in fresh medium and did not initiate cellular division. With time the cells disintegrated into cellular debris.
PMPDS-BF2 or the bimane sulfonate without light did not produce cytotoxicities.
EXAMPLE XVIII
The following case history also illustrates topical application of one of the compounds of the present invention in a 71 year old black female with a 12-year history of metastatic breast cancer spread to the chest wall. The patient had been treated with combinations of numerous
chemotherapeutic agents and radiation therapy. Her cancer continued to progress and she received nine weekly treatments with a topical 0.3% solution of 1, 3, 5, 7, 8-pentamethylpyrromethene boron difluoride-2, 6-disulfonate (PMPDS-BF 2) in dimethylsulfoxide applied to the chest wall lesions followed by exposure to a General Electric sunlamp for ten minutes. The patient had initially a greater than 50% shrinkage of her tumor, which lasted over nine weeks. She demonstrated no toxic reactions. After a nine week shrinkage, the metastatic lesions again began to grow.
For PDT, any of the compounds of the present invention are used as in Example X-XII. As used in this specification, the term "lower alkyl" refers to an alkyl group having 1-4 carbons. A class of substituents "selected independently" from a group means that any of the substituents can be any of the listed substituents and that the substituents in the class need not be identical (although they may be). The notation R1, R2...Rx= A, B or C or R1, R2...Rx=A, B or c shall be interpreted to mean that any R can be any of A, B or C.
The term "electron withdrawing group" means a group (such as a CN containing group) that withdraws electron density.
Having herein described a preferred embodiment of the invention, it is contemplated that suitable modifications may be made by those skilled in the art. For example, a variety of different compounds using the basic tri-cyclic structure presented herein may be used as laser dyes and/or photodynamic therapy agents. Thus, the invention shall only be construed in accordance with the following claims.

Claims

1. A method for inducing tissue injury in
targeted neoplastic animal tissue, comprising the steps of:
administering to said animal an amount of a compound that is cytotoxic when the compound is illuminated, the compound having the formula:
(a)
Figure imgf000060_0001
wherein
R1 is selected independently from the group consisting of C, N, B, Zn, Mg, and Cu, R2, R3, R5, R6, R8, R9, R1 1, and R12 are independently selected from the group consisting of C and N;
R4 and R10 are independently selected from the group consisting of C, N, O, and S; R7 is selected independently from the group consisting of C, N, B, Zn, Mg, and Cu; R13-R19 are selected independently from the group consisting of H, F, Cl, Br, I, CN, NC, NO, NO2, NH2, NCO, CO2H, CONH 2, phenyl, naphthyl, pyrryl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, ArF, ArN2, and NHCOAr where Ar = phenyl or naphthyl,
CnH2n+ 1, where n is an integer from 1 t0 3' CnF2n+ 1, (CnF2n+ 1)CO, CO2C2F2n+ 1, (CH2)nF, (CH 2)nCl,
(CH2)nBr, (CH2)nI, (CH2)nCN, (CH2)nNC, (CH2)nNO2, (CH2)nNO, (CH 2)nCO(C nF2n+ 1),
(CH2)nCO2H, and (CH2)nNH2, where n is an integer from 1 to 3, SO3M and CO2M where M is Na or K, cyclic alkyl groups having the formula CnH2n-1 where n is an integer from 4 to 6, CnH2n 2 and olefin derivatives having the formula CnH2n-1 where n is an integer from 2 to 4, RCO, CO2R, CONHR, CON(R) 2, NHR, N(R) 2, NHCOR, C(NOR)R, SO3R, SO2R, PO3R, (CH2)nCOR, (CH2)nSO3R, (CH2)nSO2R, (CH2)nNHR, (CH 2)nN(R) 2, and (CH2)nNHCOR where R = CnH2n+ 1 and n is an integer from 1 to 4, CnH2n-m where n is an integer from 2 to 3 and m is an integer from 2 to 3, (CH2)nAr, (CH2)nArN2, and (CH2)nNHCOAr where Ar = phenyl or naphthyl and n is an integer from 1 to 3, (CH2)nHet where Het = pyrryl. pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl and n is an integer from 1 to 3, and (CH2)nSO3M where M = Na or K and n is an integer from 1 to 3;
R20 and R21 are independently selected from the group consisting of H, F, phenyl, naphthyl, and CnH2n+ 1 where n is an integer from 1 to 4; and
(b)
Figure imgf000061_0001
wherein R is selected independently from the group consisting of lower n-alkyl and t-alkyl
(c)
Figure imgf000061_0002
wherein X is selected independently from the group consisting of CH and N; and Y is selected independently from the group consisting of CH and N (d)
Figure imgf000062_0002
wherein W is selected independently from the group consisting of lower n-alkyl, lower t-alkyl, and CN; and Y is selected independently from the group consisting of lower n-alkyl, lower t-alkyl, or
CH=CHCN, and Z is selected independently from the group consisting of lower n-alkyl and lower t- alkyl; and
(e)
Figure imgf000062_0001
wherein R is H or lower n-alkyl or t-alkyl.
after administering said compound, exposing the targeted tissue to a sufficient amount of light of a sufficient wavelength for a sufficient period of time to cause cytotoxic injury to the targeted tissue.
2. The method of claim 1(a) wherein R1-R5 and R9-R 12 = C.
3. The method of claim 2 wherein R13, R14, R15, R17, and R18 = lower n-alkyl.
4. The method of claim 3 wherein R6 and R8 = N.
5. The method of claim 4 wherein R7 = B.
6. The method of claim 5 wherein R20 and R21 = F.
7. The method of claim 1(a) wherein the compound has the formula of claim 1(d).
8. A method of inducing tissue injury in targeted neoplastic animal tissue, comprising the steps of:
administering to said animal an amount of a compound that is cytotoxic when the compound is illuminated, the compound having the formula:
(a)
Figure imgf000063_0001
wherein X is H or lower n-alkyl or SO-3, and Y is lower n-alkyl or an electron withdrawing group; or
(b)
(c)
Figure imgf000064_0001
wherein X and Y are independently selected from the group consisting of CH and N, and R is lower alkyl; or
(d)
Figure imgf000064_0002
wherein W = lower alkyl or CN; and Y and Z are selected from the group consisting of lower alkyl and CH=CHCN; or (e)
Figure imgf000065_0002
wherein R is H or lower alkyl;
after administering said compound, exposing the targeted tissue to a sufficient amount of light of a sufficient wavelength for a sufficient period of time to cause cytotoxic injury to the targeted tissue.
9. The method of claim 8 wherein the compoimd is selected from the group consisting of
(a)
(b)
Figure imgf000065_0001
wherein X and Y are independently selected from the group consisting of CH and N, and at least one of X and Y is N, and R is lower alkyl.
(c)
Figure imgf000066_0002
wherein W = lower alkyl or CN; and Y and Z are independently selected from the group consisting of lower alkyl and CH=CHCN, and at least one of Y and Z is CH=CHCN; and
(d)
Figure imgf000066_0001
wherein R is H or lower alkyl.
10. A compound comprising any of the compounds of claim 8.
11. A compound comprising any of the compounds of claim 9.
12. The method of claim 9 wherein the compound is
Figure imgf000067_0001
13. The method of claim 1 wherein the compound is administered by (a) injection into the targeted neoplastic animal tissue; or (b) topical application to the targeted neoplastic animal tissue.
14. The method of claim 1 wherein the compound is administered systemically to the animal and the targeted neoplastic tissue is exposed to a sufficient amount of light of a sufficient wavelength to cause cytotoxic injury to the targeted tissue.
15. The method of claim 1 wherein said exposing step comprises exposing the targeted tissue to a light source selected from the group consisting of a laser and a sun lamp.
16. A method for inducing tissue injury in targeted neoplastic animal tissue, comprising the steps of
administering to said animal an amount of a compound that is cytotoxic when the compound is illuminated, the compound having the formula (a)
Figure imgf000068_0001
wherein W = CH3, CH2CH3, CH(CH 3)2, c - C6H 11, CH2OCOCH 3, p - (CH3)2NC6H5, p - CH3OC6H5, H, or CN;
X = CH3, H, C6H5, or CH,CH3;
Y = H, CH3, CH2CH3, (CH2)2CH3, C(CH 3)3, n-butyl, C6H5, NHCOCH 3, or
CO2CH2CH3; and
wherein Y and Z can also be a ring -(CH2)4-, or X and Y can be a ring -(CH2)3-; (b)
Figure imgf000068_0002
wherein R is H or lower alkyl;
(c)
Figure imgf000068_0003
wherein X is CH or N; Y is CH or N; and R is lower alkyl; or (d)
Figure imgf000069_0002
wherein W = lower alkyl or CN; and R = lower n-alkyl or CH=CHCN; and
(e)
Figure imgf000069_0001
wherein R is selected from the group consisting of H, lower n-alkyl, and lower t-alkyl.
17. A composition comprising the compound of claim 16 and a carrier solvent in which the compound can fluoresce.
18. The method of claim 16(a) wherein the compound is selected from the group consisting of
Figure imgf000070_0001
19. A compound having the formula
(a)
Figure imgf000071_0001
wherein the compound is selected from the group consisting of
Figure imgf000071_0002
(b)
Figure imgf000072_0001
wherein R is H or lower alkyl;
(c)
Figure imgf000072_0002
wherein X is CH or N, Y is CH or N, and R is lower alkyl;
(d)
Figure imgf000072_0003
wherein W is lower alkyl or CN and R is lower alkyl or CH = CHCN; and
Figure imgf000073_0001
wherein R is selected from the group consisting of H and lower alkyl.
20. The compound of claim 19 wherein the compound is selected from
Figure imgf000073_0002
21. The compoimd of claim 20 wherein W is CN.
22. The compound of claim 19 comprising
(a)
Figure imgf000074_0001
wherein R is H or lower alkyl;
(b)
Figure imgf000074_0002
wherein X is CH, Y is N, and R is lower alkyl; or
(c)
Figure imgf000074_0003
wherein W is CN, and R is lower alkyl or CH=CHCN.
23. The compound of claim 22 wherein the compound is 22(a).
24. The compound of claim 22 wherein the compound is 22(b).
25. The compound of claim 22 wherein the compound is 22(c).
PCT/US1994/002033 1993-02-19 1994-02-18 Chemical compounds useful in photodynamic therapy and production of laser light WO1994019355A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP94909795A EP0684950A4 (en) 1993-02-19 1994-02-18 Chemical compounds useful in photodynamic therapy and production of laser light.
JP6519283A JPH08509471A (en) 1993-02-19 1994-02-18 Compounds useful for photodynamic therapy and generation of laser light

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US020,293 1993-02-19
US08/020,293 US5446157A (en) 1990-04-23 1993-02-19 Boron difluoride compounds useful in photodynamic therapy and production of laser light

Publications (1)

Publication Number Publication Date
WO1994019355A1 true WO1994019355A1 (en) 1994-09-01

Family

ID=21797791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002033 WO1994019355A1 (en) 1993-02-19 1994-02-18 Chemical compounds useful in photodynamic therapy and production of laser light

Country Status (5)

Country Link
US (1) US5446157A (en)
EP (1) EP0684950A4 (en)
JP (1) JPH08509471A (en)
CA (1) CA2156508A1 (en)
WO (1) WO1994019355A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068431A1 (en) * 2001-02-27 2002-09-06 Siemens Aktiengesellschaft Organic red electroluminescent chromophores, method for the production and use thereof
FR2882056A1 (en) * 2005-02-15 2006-08-18 Centre Nat Rech Scient DIPYRROMETHENES-BORON BOROCARBONES INSATURE
FR2882055A1 (en) * 2005-02-15 2006-08-18 Centre Nat Rech Scient DIBENZOPYRROMETHENES-BORON BOROCARBONES UNSATURATED
WO2011071360A3 (en) * 2009-12-10 2011-09-22 Universidad De Guanajuato Synthesis of 8-aminoboron-dipyrromethenes having blue fluorescence
WO2015077427A1 (en) 2013-11-20 2015-05-28 The University Of Akron Highly Fluorescent Pyrrole-BF2 Chromophores
CN105238092A (en) * 2015-10-30 2016-01-13 东莞理工学院 Novel 2,6-site-substituted BODIPY organic dye sensitizer and preparation method therefor
US9273078B2 (en) 2013-12-05 2016-03-01 The University Of Akron Half-phthalocyanine-like chelates and synthesis thereof
CN107603271A (en) * 2017-10-19 2018-01-19 南京林业大学 A kind of preparation method of long-chain alkoxy base BODIPY compounds
US10669474B2 (en) 2016-10-04 2020-06-02 Toray Industries, Inc. Light source unit, and display and lighting device each including same
CN111560033A (en) * 2020-05-14 2020-08-21 遵义医科大学 Synthesis method of light controlled release compound and application of light controlled release compound in tumor treatment

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852191A (en) * 1995-06-07 1998-12-22 Carnegie Mellon University Rigidized monomethine cyanines
US5579429A (en) * 1995-09-06 1996-11-26 Dn Labs, Inc. Laser dye doped fluorescent optical fiber and method of preparation of the same
US5869689A (en) * 1995-10-17 1999-02-09 Molecular Probes, Inc Stains for acidic organelles
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
US5786219A (en) * 1996-10-28 1998-07-28 Molecular Probes, Inc. Microspheres with fluorescent spherical zones
AU741076B2 (en) 1996-12-12 2001-11-22 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6106999A (en) * 1997-08-12 2000-08-22 Mitsui Chemicals Photosensitizer, visible light curable resin composition using the same, and use of the composition
GB2344688A (en) 1998-12-08 2000-06-14 Secr Defence Organic light emitting diode device
US6254594B1 (en) * 1999-07-30 2001-07-03 Quadrivium, Llc Disposable light source for photothermal treatment of human tissue
EP1211307A4 (en) * 1999-09-09 2006-05-10 Toudai Tlo Ltd Method of piercing membrane and apparatus therefor
EP1492799B1 (en) * 2002-03-22 2013-09-11 HAE Therapeutics Limited Compounds useful as photodynamic therapeutic agents
US20040087842A1 (en) * 2002-05-30 2004-05-06 Lakowicz Joseph R. Fluorescent probes for saccharrides
US6903214B1 (en) * 2003-12-11 2005-06-07 Eastman Kodak Company Synthesis of bis(azinyl)amine-BF2 complex
ES2454551T3 (en) * 2004-12-28 2014-04-10 Gemin X Pharmaceuticals Canada Inc. Dipyrrolic compounds, compositions, and methods for the treatment of cancer or viral diseases
EP2022794B1 (en) * 2006-04-28 2017-08-23 Keio University Fluorescent compound and labeling agent comprising the same
WO2009025767A1 (en) * 2007-08-17 2009-02-26 Research Foundation Of The City University Of New York Boron dipyrromethene difluoro (bodipy) conjugates
EP2284541A1 (en) 2009-08-12 2011-02-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Fluorescence-based imaging and analysis of cells and cellular components using lipophilic dyes with improved specificity, spectral property and photostability
US8715529B1 (en) 2012-01-23 2014-05-06 Arrowhead Center, Inc. Synthesis and applications of triazaborolopyridinium compounds and substituted triazaborolopyridinium compounds and methods of use
TWI557187B (en) * 2012-05-03 2016-11-11 拜耳材料科學股份有限公司 Novel photoinitiators for photopolymers
EP2680005A1 (en) 2012-06-28 2014-01-01 Rheinische Friedrich-Wilhelms-Universität Bonn Lipid analysis
CA2927521C (en) * 2013-10-17 2023-02-07 Dic Corporation Resin composition and molded article
JP6558243B2 (en) 2014-02-05 2019-08-14 東レ株式会社 Photoelectric conversion element and image sensor
KR102204111B1 (en) 2014-04-17 2021-01-15 삼성전자주식회사 Compound and organic photoelectronic device and image sensor
US9733187B2 (en) * 2015-03-06 2017-08-15 King Saud University Method of detecting bladder cancer by optical analysis of bodily fluids
EP3305870B1 (en) * 2015-05-26 2020-11-18 Toray Industries, Inc. Pyrromethene-boron complex, color-changing composition, color-changing film, light source unit including same, display, and lighting
KR102344621B1 (en) 2015-07-17 2021-12-30 도레이 카부시키가이샤 Color conversion composition, color conversion film, and backlight unit, display and lighting comprising same
KR102336862B1 (en) 2015-09-29 2021-12-08 도레이 카부시키가이샤 Color conversion film, and light source unit, display and lighting device comprising same
US10400165B2 (en) 2015-10-09 2019-09-03 Toray Industries, Inc. Color conversion composition, color conversion sheet and light source unit including the same, display, lighting apparatus, backlight unit, LED chip, and LED package
JP6380653B2 (en) 2016-02-19 2018-08-29 東レ株式会社 Color conversion sheet, light source unit including the same, display and lighting device
MY188668A (en) 2016-03-25 2021-12-22 Toray Industries Light source unit, laminated member, and display and lighting apparatus including them
CN109661599B (en) 2016-09-05 2021-08-10 东丽株式会社 Color conversion sheet, light emitting body including the same, and lighting device
KR102200716B1 (en) 2016-11-30 2021-01-12 도레이 카부시키가이샤 Pyromethene boron complex, color conversion composition, color conversion film, light source unit, display and lighting device
CN110612466B (en) 2017-06-02 2021-10-01 东丽株式会社 Color conversion sheet, light source unit including the same, display, and lighting device
WO2019021813A1 (en) 2017-07-28 2019-01-31 東レ株式会社 Color conversion composition and color conversion film, and light source unit, display, and lighting including same
CN111615653A (en) 2018-01-23 2020-09-01 东丽株式会社 Light emitting element, display and color conversion substrate
US20220251119A1 (en) 2019-07-24 2022-08-11 Toray Industries, Inc. Pyrromethene-boron complex, color conversion composition, color conversion film, light source unit, display, and illumination device
CN115315639A (en) 2020-03-23 2022-11-08 东丽株式会社 Color conversion composition, color conversion film, light source unit, display, and lighting and compound comprising the same
KR20230076809A (en) 2020-09-30 2023-05-31 도레이 카부시키가이샤 Color conversion sheet and light source unit including the same, display and lighting device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774339A (en) * 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US4799230A (en) * 1987-11-20 1989-01-17 The United States Of America As Represented By The Secretary Of The Navy Laser dyes derived from bimanes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0210351B1 (en) * 1985-04-30 1993-07-21 Nippon Petrochemicals Co., Ltd. Use of porphyrin derivatives in the detection and treatment of tumours
CA1340951C (en) * 1986-01-02 2000-04-11 Alan R. Moragn Production and use of purpurins, chlorins and purpurin-and chlorin-containing compositions
US4916711A (en) * 1988-09-29 1990-04-10 Boyer Joseph H Lasing compositions and methods for using the same
US5274113A (en) * 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5189029A (en) * 1990-04-23 1993-02-23 Bo-Dekk Ventures, Ltd. Indacene compounds and methods for using the same
US5248782A (en) * 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5338854A (en) * 1991-02-13 1994-08-16 Molecular Probes, Inc. Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
US5187288A (en) * 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4774339A (en) * 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US4799230A (en) * 1987-11-20 1989-01-17 The United States Of America As Represented By The Secretary Of The Navy Laser dyes derived from bimanes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0684950A4 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068431A1 (en) * 2001-02-27 2002-09-06 Siemens Aktiengesellschaft Organic red electroluminescent chromophores, method for the production and use thereof
FR2882056A1 (en) * 2005-02-15 2006-08-18 Centre Nat Rech Scient DIPYRROMETHENES-BORON BOROCARBONES INSATURE
FR2882055A1 (en) * 2005-02-15 2006-08-18 Centre Nat Rech Scient DIBENZOPYRROMETHENES-BORON BOROCARBONES UNSATURATED
WO2011071360A3 (en) * 2009-12-10 2011-09-22 Universidad De Guanajuato Synthesis of 8-aminoboron-dipyrromethenes having blue fluorescence
WO2015077427A1 (en) 2013-11-20 2015-05-28 The University Of Akron Highly Fluorescent Pyrrole-BF2 Chromophores
US10676489B2 (en) 2013-11-20 2020-06-09 The University Of Akron Highly fluorescent pyrrole-BF2 chromophores
US9273078B2 (en) 2013-12-05 2016-03-01 The University Of Akron Half-phthalocyanine-like chelates and synthesis thereof
CN105238092A (en) * 2015-10-30 2016-01-13 东莞理工学院 Novel 2,6-site-substituted BODIPY organic dye sensitizer and preparation method therefor
US10669474B2 (en) 2016-10-04 2020-06-02 Toray Industries, Inc. Light source unit, and display and lighting device each including same
CN107603271A (en) * 2017-10-19 2018-01-19 南京林业大学 A kind of preparation method of long-chain alkoxy base BODIPY compounds
CN111560033A (en) * 2020-05-14 2020-08-21 遵义医科大学 Synthesis method of light controlled release compound and application of light controlled release compound in tumor treatment

Also Published As

Publication number Publication date
EP0684950A1 (en) 1995-12-06
US5446157A (en) 1995-08-29
JPH08509471A (en) 1996-10-08
CA2156508A1 (en) 1994-09-01
EP0684950A4 (en) 1997-10-15

Similar Documents

Publication Publication Date Title
US5446157A (en) Boron difluoride compounds useful in photodynamic therapy and production of laser light
US4916711A (en) Lasing compositions and methods for using the same
US5189029A (en) Indacene compounds and methods for using the same
Watley et al. Dual functioning thieno‐pyrrole fused BODIPY dyes for NIR optical imaging and photodynamic therapy: Singlet oxygen generation without heavy halogen atom assistance
US4992257A (en) Dihydroporphyrins and method of treating tumors
Bonnett et al. Photophysical properties of meso‐tetraphenylporphyrin and some meso‐tetra (hydroxyphenyl) porphyrins
Dougherty Photochemistry in the treatment of cancer
JP5567024B2 (en) Method for producing chlorin and its use as a medicament
EP0186962A1 (en) Porphyrins and cancer treatment
Wu et al. A new near-infrared phosphorescent iridium (III) complex conjugated to a xanthene dye for mitochondria-targeted photodynamic therapy
US5162519A (en) Porphyrins and cancer treatment
Li et al. A glutathione-activatable photodynamic and fluorescent imaging monochromatic photosensitizer
AU4635993A (en) Production and use of imines of porphyrins
Kuzmina et al. Development of novel porphyrin/combretastatin A-4 conjugates for bimodal chemo and photodynamic therapy: Synthesis, photophysical and TDDFT computational studies
Cao et al. Synthesis and in vitro phototoxicity of novel π-extension derivatives of chlorin e6
Eçik et al. Design of novel photosensitizers and controlled singlet oxygen generation for photodynamic therapy
Fraix et al. A multi-photoresponsive molecular-hybrid for dual-modal photoinactivation of cancer cells
US6984656B2 (en) Core modified porphyrins
US20030013696A1 (en) Methods and compositions for photo-cross linking photoactive compounds to target tissue
Say et al. Caging of Bodipy Photosensitizers through Hydrazone Bond Formation and their Activation Dynamics
Drzewiecka et al. Tritolylporphyrin dimer as a new potent hydrophobic sensitizer for photodynamic therapy of melanoma
EP1470127B1 (en) N, n&#39;-dimethylated n-confused porphyrins
US4916127A (en) Mixed chalcogenide pyrylium salts of a Lewis base
Kumar et al. Photoinduced ring enlargement reactions of 2H-1, 2, 4-benzothiadiazine 1, 1-dioxides. Steady-state and laser flash photolysis studies
RU2164136C2 (en) Photosensitizer for photodynamic therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2156508

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994909795

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994909795

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994909795

Country of ref document: EP